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 A description of pyrrolo[1,4]benzodiazepine (PBD) biosynthesis in actinomycetes 
is a prerequisite for engineering production of analogs with enhanced antitumor activity. 
Several proteins expected to synthesize the PBD’s dihydropyrrole moiety were 
heterologously expressed, purified and assayed for activity. UV-visible spectroscopy 
revealed that predicted dioxygenases SibV and homolog Orf12 associated with PBDs 
sibiromycin and anthramycin, respectively, catalyze the regiospecific 2,3-extradiol 
dioxygenation of L-3,4-dihydroxyphenylalanine (L-DOPA) to form L-2,3-secodopa (λmax = 
368 nm). 1H NMR spectroscopy indicated that L-2,3-secodopa then spontaneously cyclizes 
into the α-keto acid tautomer of 4-(2-oxo-3-butenoic-acid)-4,5-dehydro-L-proline 1.1 (λmax 
= 414 nm). Thus, the dioxygenases establish the scaffold of the dihydropyrrole moiety. 
Both the quaternary structure and product formed by dioxygenases are conserved in 
 
 
dihydropyrrole biosynthesis within both PBD and non-PBD pathways. Stability studies 
suggest that 1.1 is relatively labile and is likely consumed rapidly by subsequent 
biosynthetic steps.  
Hydrolysis and methylation steps were proposed to modify the dihydropyrrole 
scaffold in PBDs. The predicted proteins SibS and homolog TomK associated with 
sibiromycin and PBD tomaymycin biosynthesis, respectively, were assayed for hydrolysis 
activity. The predicted protein SibZ associated with sibiromycin biosynthesis was assayed 
for methyltransferase activity. The proposed SibZ substrate 4-vinyl-4,5-dehydro-L-proline 
1.2 was synthesized. For these three proteins, no catalytic activity was observed with their 
proposed substrates or substrate precursors under a range of conditions. However, SibS 
binds 1.1 (KD = 64 ± 2 µM) suggesting it participates in dihydropyrrole biosynthesis. 
HPLC-MS indicated that SibS catalyzes the depurination of S-adenosylmethionine 
although it is unlikely this reaction is involved in sibiromycin biosynthesis. These findings 
suggest that the pathway requires revision. 
The adenylation and thiolation didomain of the predicted non-ribosomal peptide 
synthetase SibD associated with sibiromycin biosynthesis was expressed and purified. To 
test if SibD incorporates the dihydropyrrole moiety into sibiromycin, its proposed substrate 
4-propenyl-4,5-dehydro-L-proline 1.5 was synthesized. A radioactivity exchange assay and 
peptide analysis by MS revealed that SibD does not adenylate and thiolate 1.5 or its 
precursors L-DOPA, 1.1 or 1.2. However, L-threonine and the metabolic precursor L-
tyrosine are substrates for these reactions. SibB promotes adenylation catalyzed by SibD 
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Chapter 1: Introduction 
 
1.1 Pyrrolo[1,4]benzodiazepines are of pharmacological interest 
Natural products and their derivatives account for almost half of the small molecule 
anticancer drugs approved between 1940 and 2012,1 motivating continued research in the 
field. Pyrrolo[1,4]benzodiazepines (PBDs) represents a class of interest as many of its 
members display antitumor activity. PBDs contain a 1,4-benzodiazepine ring also present 
in other classes of natural products that were developed into over 50 clinically approved 
psychoactive drugs such as diazepam (Valium®, Hoffman-La Roche, New Jersey).  The 
presence of this pharmacophore makes PBDs a promising class of pharmaceuticals.2 
PBDs are tricyclic secondary metabolites, the majority of which have emerged as 
anticancer drug candidates by virtue of their ability to alkylate double stranded DNA.2-4 
PBDs contain an anthranilate and dihydropyrrole or pyrrolidine moiety fused to each side 
of a diazepine ring. The diazepine ring bears an electrophilic imine carbon C11, the site of 
alkylation.5-8 Alkylation occurs primarily at guanosine (G) (Scheme 1-1) in a sequence-
specific manner.9 5’-Pyrimidine-G-pyrimidine-3’ is the kinetic target and 5’-purine-G-
purine-3’ is the thermodynamic target.10 The resulting DNA-PBD adduct inhibits DNA 
transcription and replication. Their efficacy is due in part to their ability to bind DNA in a 
sequence selective manner within the minor grove11,12 and the resistance of their 
subsequent PBD-DNA adducts to proofreading machinery that repairs DNA.13 
Actinomycetal genera Micrococci and Streptomyces produce a variety of PBDs 
(Scheme 1-2) with a range of antitumor or other bioactivity. For instance, anthramycin 





Scheme 1-1. Antitumor activity of PBDs results from the formation of PBD-DNA adducts 
via the proposed mechanism. R and R’ represent a range of substituents. 
 
50% cell growth (GI50) = 0.029 µM and average concentration that inhibits 100% cell 
growth (TGI) = 0.61 µM).14 In contrast, neothramycin specifically targets bladder cancer 
cells when used as a topical treatment eradicating tumors in 36% of patients and reducing 
tumor size by greater than 50% in 55% of patients in one trial.15 
1.2 Sibiromycin is the most potent naturally occurring PBD 
Sibiromycin displays the highest affinity for DNA and greatest cytotoxicity of all 
PBDs due to its unique presence of an appended amino sugar.16 Thermal denaturation 
assays of calf thymus DNA-PBD complexes compared with DNA alone show sibiromycin 
is most effective at increasing the denaturation midpoint melting temperature of DNA 
(ΔTM) (Table 1-1).11,17 The ΔTM of a DNA-PBD complex compared with DNA is an 
indicator of DNA affinity of PBDs. Binding affinity was shown to correlate with the PBD’s 
ability to inhibit transcription in vitro.12 Sibiromycin is most cytotoxic to cells associated 
with leukemia and plasmacytoma (Table 1-2) and moderately cytotoxic to ovarian cancer 
cells compared with other PBDs.17 Molecular dynamics and docking studies indicate that 
its sugar protrudes from the minor groove and likely blocks transcription factors from 





Scheme 1-2. Naturally occurring PBDs with antibiotic and/or antitumor activity. 
Biosynthetic gene clusters have been identified for the boxed PBDs. 
 
utility of this natural product is limited by its cardiotoxicity that has been traced to the 




Table 1-1. Stabilization of calf-thymus DNA by PBDs as assessed by the change in 
denaturation midpoint melting temperature (∆TM) of DNA-PBD complex compared with 
DNA alone.17 
 
 ∆TM (°C)a 
PBD 0 h 4 h 18 h 
Sibiromycin 15.7 15.9 16.3 
Anthramycin 9.4 11.2 13.0 
Tomaymycin 1.0 2.4 2.6 
a DNA-PBD at a 5:1 molar ratio was incubated at various times at 37 °C and pH 7.0. 
 
Table 1-2. Cytotoxicity of PBDs against various cancer cells as assessed by the half 










Sibiromycin 2.9 nM 0.017 nM 40 nM 
Anthramycin 22 nM 2.8 nM 320 nM 
Tomaymycin 3.7 nM 1.8 nM 0.13 nM 
 
1.3 Efforts to develop PBD analogs into chemotherapeutic drugs 
To circumvent the harmful side effect of sibiromycin, monomeric and dimeric PBD 
analogs were chemically synthesized.20,21 SG2000 (formerly SJG-136) (Figure 1-1), the 
most potent synthetic PBD dimer is currently in Phase II trials for treating leukemia 
(AstraZeneca (Spirogen), London, UK). However, development of other synthetic analogs 
has been impeded by a number of issues. Installing the C2-endo-exo unsaturation is 
laborious and lengthy, particularly because a ring closure step that furnishes the diazepine 
ring through reductive cyclization removes the unsaturation in the dihydropyrrole. The 
unsaturation is necessary to flatten the ring allowing it to fit into the minor groove.17 A 
fully unsaturated and saturated hydropyrrole ring or bulky substituents on the hydropyrrole 
ring inhibit PBD analogs from binding DNA.22 Synthetic methodologies are also not easily 
compatible with modifying the substituents on the anthranilate ring without hindering the 
diazepine ring formation and perturbing two of its crucial structural attributes, the S-
stereochemistry at C11a and the N10-C11 imine bond. Replacing the anthranilate ring with 
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other heterocycles such as pyridine, pyrazine, pyrimidine or pyrazole decreases binding 
affinity and potency of the resulting analog17 prompting interest in pursuing other avenues 
of PBD analog production. 
 
Figure 1-1. SG2000, a synthetic PBD dimer. 
Biosynthesis offers a complementary and appealing strategy to generate new PBD 
candidates. For example, delineating the biosynthesis of the anthranilate moiety in 
PBDs23,24 allowed for its reprogramming to create an analog of sibiromycin lacking its C9 
hydroxyl group.25 The resulting 9-deoxysibiromcyin (Scheme 1-3) minimizes 
cardiotoxicity as desired25 and confirms the potential for creating a range of new PBDs that 
suppress unwanted side effects. 
 
 
Scheme 1-3. Natural product sibiromycin and its bioengineered analog 9-
deoxysibiromycin. The hydroxyl group inducing the cardiotoxic property of sibiromycin 
is indicated with a red box. 
 
Creating a dihydropyrrole moiety within a PBD to abolish the abnormal DNA 
bending caused by its alkylation is an attractive goal since the resulting adduct has the 
potential to evade DNA repair enzymes that detect alteration in DNA curvature.13 Some of 
the distortion caused by PBDs is already ameliorated by their right-handed twist that 
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complements right-handed duplex DNA.7,8,26-29 Structure perturbation of the conjugate still 
persists and includes bending of the helix around the newly formed covalent bond. The 
degree of DNA bending induced by the adduct (5.0-8.9° with anthramycin and 8.2-14.5° 
with tomaymycin) inversely correlates with the degree of PBD twist (35.4° in anthramycin 
and 9.1° in tomaymycin).26,27 Before natural processes can be harnessed to develop the new 
dihydropyrroles within PBDs to escape DNA repair, the biosynthetic pathway of these 
groups must be identified. 
1.4 Current understanding of dihydropyrrole moiety biosynthesis 
Previous feeding studies with radiolabeled amino acids first suggested that the 
dihydropyrrole moiety originates from L-tyrosine,30 but few biochemical details of the 
intervening transformations are available. A comparison of the gene clusters responsible 
for producing the PBDs anthramycin,23 sibiromycin (Figure 1-2),31 tomaymycin32 and 
porothramycin33 allowed a tentative assignment of gene function and revealed a common 
strategy for generating these PBDs. The biosynthetic gene clusters have not been identified 
for the remaining PBDs or a pair of pentacyclic PBD derivatives called circumdatins 
(Scheme 1-4). The biosynthetic gene cluster is available for tilivalline (Scheme 1-4), a 
toxic PBD derivative implicated in causing hemorrhagic colitis upon its overproduction by 
Klebsiella oxytoca, a member of the human intestinal microbiota.34 However, no genes 
associated with pyrrolidine moiety biosynthesis are present in the gene cluster suggesting 
this moiety does not form from L-tyrosine. More information on the moiety was gleaned 
instead from biosynthetic gene clusters of non-PBD natural products lincomycin A35,36 and 
hormaomycin37 as both contain a pyrrolidine ring that also originates from L-tyrosine and 
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Figure 1-2. Genetic organization of the sibiromycin biosynthetic gene cluster in 
Streptosporangium sibiricum. Functional assignment of its gene products was based on the 
comparative analysis of the PBDs, lincomycin A and hormaomycin biosynthetic gene 
clusters. This figure was reproduced.31 
 
 
Scheme 1-4. Naturally occurring PBDs with no antitumor activity reported. Tilivalline is 
an enterotoxic PBD produced by a human gut microbe while no known bioactivity has 
been observed for the pair of circumdatins. The boxed PBD has an identified biosynthetic 
gene cluster. 
 
In vitro activity assays confirmed that this pathway begins with an enzyme-
catalyzed ortho-hydroxylation of L-tyrosine to form L-3,4-dihydroxyphenylalanine (L-
DOPA).38,39 L-[14C]DOPA was partially incorporated into the PBD during feeding studies 
providing further evidence that L-DOPA is a pathway intermediate.40  The subsequent steps 
have been tentatively proposed31 (Scheme 1-5) based on feeding studies (Scheme 1-6), the 
comparison of available gene clusters (Figure 1-2) and functional assignment of gene 
products based on the identification of consensus sequence signatures using BLAST41 
(Table 1-3). These steps are expected to be common during the production of sibiromycin, 
anthramycin, porothramycin, tomaymycin, lincomycin A and hormaomycin as part of their 
gene clusters codes for similar a set of enzymes. The amino acid sequences of SibV and its 
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homologs are similar to dioxygenases suggesting they catalyze L-DOPA dioxygenation to 
form the dihydropyrrole scaffold 1.1. The radiolabeling experiments indicated that two of 
the aromatic carbons in both L-[14C]- tyrosine and L-[14C]-DOPA did not get incorporated 
into the final PBD.40 To account for this observation, a step is necessary to shorten the four-
carbon side chain of the heterocycle in 1.1. SibS and homologs are proposed to catalyze 
the hydrolysis of 1.1 to a vinyl dihydropyrrole 1.2. SibZ and its homologs contain SAM-
binding motifs and belong to a methyltransferase superfamily suggesting that they catalyze 
a methylation of 1.2 to form the 1-pyrroline 1.3. The terminal carbon in the three-carbon 
side chain observed in the dihydropyrrole and pyrrolidine moieties derive from L-
methionine (Scheme 1-6) presumably via the methyl donor S-adenosylmethionine (SAM). 
This supports the site of methylation. The SibZ homolog in tomaymycin biosynthesis is 
absent. This is consistent with the presence of a two-carbon side chain in its pyrrolidine 
moiety. SibT and its homologs belong to a flavin-utilizing superfamily, members of which 
resemble oxidoreductases. SibT is proposed to reduce the 1-pyrroline ring in 1.3 into a 
pyrrolidine derivative 1.4 using an F420-based cofactor. F420, structurally similar to flavin 
cofactors is a two-electron carrier that transfers hydride in a redox reaction. F420 is 
modified with a poly-glutamate tail (F420-GluN). SibY and its homologs belong to a γ-
glutamyltranspeptidase superfamily suggesting they transfer an unknown number of 
glutamyl residues to F420. The proposed substrate 1.3 in the reduction reaction 
accumulated in a mutant strain of the lincomycin A producer Streptomyces lincolnensis, 
incapable of producing the F420 cofactor.42 This supports the order of the hydrolysis and 
methylation steps as preceding the reduction of the ring. The reduction step represents a 
branching point in the pathways after which predicted enzymes unique to each natural 
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product impart structural differences in the moiety to produce distinct natural products. The 
resulting dihydropyrrole or pyrrolidine moiety is eventually incorporated into the natural 
product most likely by a non-ribosomal peptide synthetase (NRPS) or an NRPS-like 
protein present in the organism. For example, the putative NRPS SibD is proposed to 
incorporate the dihydropyrrole moiety into sibiromycin. This proposed pathway reconciles 
the putative roles of each enzyme with a chemically efficient biosynthetic route. 
 
Scheme 1-5. Proposed biosynthetic pathway of the dihydropyrrole in sibiromycin. The 
boxed biosynthetic intermediate accumulated in a PBD producing strain (S. lincolnensis) 
that was mutated to incapacitate synthesis of the F420 cofactor. 
 
Confirming the biosynthetic steps of the PBD dihydropyrrole moiety is a 
prerequisite to the development of engineered PBDs in the future. Of primary interest are 
the initial steps of the pathway as this facilitates engineering pathways in multiple PBD 
producers. As sibiromycin is the most potent naturally occurring PBD and was successfully 





Scheme 1-6. The L-tyrosine and L-methionine precursors ultimately form the 
dihydropyrrole and pyrrolidine moiety depicted in red and green, respectively, in PBDs 
sibiromycin, tomaymycin, anthramycin and porothramycin and natural products 
lincomycin A and hormaomycin. 
 
further engineering it in the future. This entailed the heterologous expression, purification 
and characterization of SibV, expected to form the dihydropyrrole scaffold, SibS and SibZ, 
expected to modify the dihydropyrrole exocyclic carbon chain and SibD, expected to 





















Table 1-3. Deduced function of proteins encoded by dihydropyrrole and pyrrolidine 
biosynthetic gene cluster. The sibiromycin dihydropyrrole biosynthetic gene cluster 
(GenBank accession number FJ768674) were compared with homologous ones involved 
in tomaymycin (GenBank accession number FJ768957), anthramycin (GenBank accession 
number EU195114), porothramycin (GenBank accession number HQ872605), lincomycin 
A (GenBank accession number EU124663) and hormaomycin (GenBank accession 





Function  Homologsa Identity/Similarity 
(%)b 
SibD Putative non-ribosomal peptide 
synthetase 





   HrmP 37/50 


















   HrmF 52/63 





































a Protein names of sibiromycin start with Sib, tomaymycin start with Tom, anthramycin start with Orf, 
porothramycin start with Por, lincomycin A start with Lmb and hormaomycin start with Hrm. 
b Percent identity and similarity were determined using BLAST. 
c Only the adenylation domain sequence in SibD was aligned with the standalone LmbC adenylase.  







Chapter 2: Dihydropyrrole Scaffold Formation by SibV 
 
2.1 Introduction 
 The PBD dihydropyrrole moiety derives from L-tyrosine according to the 
incorporation pattern of radiolabeled amino acids fed to PBD producers.30 Only the initial 
step of this pathway, an ortho-hydroxylase-catalyzed transformation of L-tyrosine to L-
DOPA, has been verified experimentally in vitro.38 A biosynthetic route that transforms L-
DOPA to the dihydropyrrole ring was devised23 based on chemistry commonly used by 
bacteria to degrade aromatic compounds.43 Specifically, these catabolic pathways involve 
a cleavage of catechols similar to L-DOPA through a dioxygenation reaction. This step 
incorporates dioxygen into the aromatic ring to cleave a carbon-carbon bond either between 
the two hydroxyls (intradiol dioxygenation) to form a dicarboxylic acid or adjacent to one 
of the hydroxyls (extradiol dioxygenation) to form a semialdehyde (Scheme 2-1).44 In the 
case of L-DOPA, extradiol dioxygenation was proposed to form the semialdehyde L-2,3-
secodopa that could then cyclize into the dihydropyrrole 1.1 (Scheme 2-2).23 The action of 
dioxygenation is reasonable as the sibiromycin gene cluster, representative of the other 
PBD gene clusters, contain two genes that code for putative dioxygenases.31 
The sibV gene from the sibiromycin gene cluster codes for SibV, a protein proposed 
to catalyze dioxygenation of L-DOPA.31 SibV shares higher sequence homology with 
enzymes predicted to be dioxygenases (protein hits with 38-66% sequence identity and 
expect values from 10-26 to 10-65) and lower sequence homology with enzymes predicted 
to be a lactoylglutathione lyase (protein hits with 27-35% sequence identity and expect 




Scheme 2-1. PBD biosynthesis is expected to involve oxidative cleavage of a catechol, a 
reaction observed during microbial degradation of aromatic compounds.23 
 
 
Scheme 2-2. The dihydropyrrole 1.1 may form via dioxygenation of L-DOPA into L-2,3-
secodopa followed by intramolecular cyclization to a common biosynthetic intermediate 
of PBD.2 
 
of SibV contains part of the catechol 2,3-extradiol dioxygenase consensus sequence 
signature (Hx7FYx2DPxGx3E).45 The histidine and phenylalanine are both replaced with 
valine. Homologs of SibV are present in the anthramycin,23 porothramycin,33 
tomaymycin,32 lincomycin A46-48 and hormaomycin37 biosyntheses. All of their pathways 
are proposed to involve the equivalent dioxygenation step as the second step in the 
biosynthesis of their respective dihydropyrrole and pyrrolidine moieties. In vitro assays 
showed that LmbB146-48 from lincomycin A biosynthesis and HrmF37 from hormaomycin 
biosynthesis catalyze a reaction with L-DOPA as the substrate to form a yellow product 
making SibV the likely dioxygenase of interest. 
The sibiromycin gene cluster codes for another protein (SibP) with high sequence 
similarity to putative dioxygenases.31 However, its amino acid sequence does not contain 
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any portion of the catechol 2,3-extradiol dioxygenase consensus signature sequence45  
suggesting its substrate is not a catechol like L-DOPA. SibP belongs to the tryptophan 2,3-
dioxygenase superfamily according to BLAST analysis (domain hits with expect values 
from 10-46 to 10-87). Members of this superfamily use tryptophan or indolamine as 
substrates. Thus, SibP is proposed to cleave L-tryptophan, to initiate the transformation of 
the metabolic precursor to the anthranilate moiety (Scheme 2-3). The anthranilate moiety 
is common to PBDs and absent in lincomycin A and hormaomycin. This is in agreement 
with predicted SibP homologs present only in anthramycin, porothramycin and tilivalline 
biosynthetic pathways and absent in tomaymycin, lincomycin A or hormaomycin 
biosynthetic pathways. The anthranilate moiety in tomaymycin is derived from the 
shikimate pathway instead of L-tryptophan32 explaining the absence of a SibP homolog in 
this particular PBD biosynthetic pathway. Taken together, the phylogenetic comparison 
shows that SibP is unlikely to catalyze the dioxygenation of L-DOPA, confirming that SibV 
is the most likely protein to catalyze the reaction. 
 
Scheme 2-3. SibP and its homologs are proposed to catalyze dioxygenation of L-tryptophan 
to initiate anthranilate moiety biosynthesis of PBDs sibiromycin, anthramycin, 
porothramycin and tilivalline.2 
 
 SibV and its homologs are expected to transform L-DOPA into L-2,3-secodopa that 
has the potential to cyclize into the five-membered ring found in the PBD dihydropyrrole 
moiety (Scheme 2-4). However, multiple sites of cleavage and alternative cyclizations 
observed with other 2,3-extradiol dioxygenases could yield a plethora of possible products. 
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To confirm the dioxygenation step, SibV was produced and incubated with L-DOPA. The 
product(s) formed were identified and characterized. The SibV homolog in anthramycin 
(Orf12) was also similarly tested to determine the generality of this step along the path to 
the dihydropyrrole moiety. 
 
 
Scheme 2-4. Two tautomers, 1.1 and 2.1 and a side product muscaflavin may form via L-
2,3-secodopa that is generated from oxidative cleavage of L-DOPA. 
 
2.2 Results and Discussion 
 Production of dioxygenases. The putative dioxygenases associated with formation 
of the dihydropyrrole moiety in Streptomyces refuineus’s anthramycin (Orf12) and 
Streptosporangium sibiricum’s sibiromycin (SibV) were selected as representative of the 
general type of transformation. Orf12 and SibV were alternatively fused with an N-terminal 
His6 and His6-SUMO tag, respectively. Each was then expressed in BL21 (DE3) 
Escherichia coli and purified via Ni-NTA chromatography. The tag of SibV was removed 
by a SUMO-specific protease (Ulp1)49 leaving behind a single non-native N-terminal 
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serine. The dioxygenases were purified to near homogeneity by size exclusion 
chromatography and reconstituted with Fe2+ to yield light blue holo-dioxygenases. The 
final purification step provided ca. 150 mg His6-Orf12 (Orf12) and 10 mg SibV per liter 
of growth media (Appendix A-1). Since His6 tags sometimes interfere with protein 
oligomerization,50,51 the oligomeric state of SibV, separated from its His6-SUMO tag 
during purification, was examined by gel filtration. SibV was confirmed to form its 
expected dimer in solution (observed molecular mass of 34.6 kDa, theoretical monomeric 
mass of 17.1 kDa predicted by ExPASy ProtParam) (Appendix A-2). Gel filtration was 
used to determine that LmbB1 is also a dimer in solution47 indicating that the 
oligomerization state of dioxygenases is conserved among the PBD and lincomycin A 
biosynthetic pathways. 
 UV-visible spectroscopic characterization of the transient and final products 
formed by dioxygenase treatment of L-DOPA.  Transformation of L-DOPA by Orf12 
generated a transient compound (Amax at 378 nm) that subsequently diminished concurrent 
with formation of a yellow compound (Amax at 414 nm) (Figure 2-1). SibV transformed L-
DOPA to the same transient and final products as evidenced by equivalent changes in UV-
visible absorbance (Appendix A-3). Thus, these two dioxygenases appear to promote 
identical reactions. The same Amax at 414 nm was observed previously after turnover of 
dioxygenases LmbB1 and HrmF in lincomycin A48 and hormaomycin37 indicating that this 
transformation is not limited to PBD biosynthesis but general to pyrrolidine biosynthesis 




Figure 2-1. UV-visible spectroscopy of transient (Amax = 378 nm) and yellow (Amax = 414 
nm) species during dioxygenation of L-DOPA catalyzed by Orf12. The reaction between 
L-DOPA (1.0 mM) and Orf12 (4.9 µM) was performed in sodium phosphate (250 mM) at 
pH 8.0. Scans were recorded every 20 sec for a total of 120 sec. 
 
 1H NMR spectroscopic analysis of the product formed by dioxygenation of L-
DOPA catalyzed by Orf12. The yellow compound generated in the dioxygenase-
catalyzed transformation of L-DOPA was isolated by extraction and characterized by 1H 
NMR spectroscopy. This required a concentrated sample but oxygen-dependent 
inactivation of the enzyme made it necessary to add Orf12 in multiple aliquots to 
compensate for its loss of activity. The enzyme was subsequently removed by precipitating 
it with CHCl3. The remaining reaction mixture in the aqueous phase was spiked with 10% 
D2O and then analyzed by NMR spectroscopy. No signals associated with L-DOPA were 
observed indicating its complete consumption (Figure 2-2). Assignment of the 1H signals 
was based on a model compound 1.3, previously proposed as a downstream intermediate 
in the biosynthesis of the dihydropyrrole moiety (Scheme 1-5).42 The chemical shifts, 
integration values and coupling constants were all consistent with 4-(2-oxo-3-butenoic-
acid)-4,5-dehydro-L-proline, 1.1. The signals located upfield of the HDO resonance were 
diagnostic of protons attached to sp3 hybridized carbons and were assigned to H5α (3.11 
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ppm), H5β (2.72 ppm) and H4 (4.59 ppm) (Figure 2-2). These three signals are each a 
doublet of doublets arising from an AMX spin system that forms from coupling between 
the diastereotopic methylene protons H5α and H5β (2JHH = 16 Hz) and are further split by 
H4 at the adjacent chiral center. Vicinal coupling constants between H5α and H4 (3JHH = 
12 Hz) and between H5β and H4 (3JHH = 6.2 Hz) satisfied the Karplus relationship52 that 
correlates vicinal coupling constants to dihedral angles (predicted to be 2.9° and 117.2° by 
Chem3D Pro, respectively). The resonance furthest downfield (7.59 ppm) was a singlet 
and consistent with proton H3 located on the unsaturated carbon in the dihydropyrrole. The 
remaining pair of doublets H1 (5.52 ppm) and H2 (7.58 ppm) were assigned to vicinal 
protons. The large HDO signal distorted the baseline beneath the H1 and H4 resonances 
and suppressed their integration from the expected value of one. 1H-1H COSY analysis 
confirmed the expected connectivities between the protons with the exception of H4 
(Appendix A-4). Its resonance is located near that of the solvent and was not observed due 
to solvent suppression. No aldehydic protons (9-10 ppm) were observed that would have 
indicated the formation of alternative products as discussed below (Scheme 2-4). 
The multiplicity of signals for the pair of vicinal protons H1 and H2 were used to 
distinguish between the tautomers 1.1 and 2.1. These protons produced a large coupling 
constant (3JHH = 16 Hz) that is consistent with vicinal coupling constants of trans-olefinic 
protons (3JHH expected = 12-18 Hz) such as those in the α-keto acid tautomer 1.1 but not in 
the α-enol acid tautomer 2.1. This alternative would have exhibited a lower vicinal 
coupling constant (3JHH expected < 11 Hz).53 A pair of weaker signals (7.12 and 5.80 ppm) 
exhibits a coupling constant (8.5 Hz) consistent with the equivalent protons on 2.1. 




Figure 2-2. Annotated 1H NMR (500 MHz, 10% D2O, H2O suppression with presaturation) 
spectrum of 1.1 formed by dioxygenation of L-DOPA catalyzed by Orf12. The solvent 
signal was truncated for clarity. 
 
coefficient determined for 1.1 at pH 8.0 (ε414 nm = 50 ± 3 mM-1cm-1) closely matches those 
reported for the LmB1 product (ε413 nm = 48 ± 2 mM-1cm-1 and ε414 nm = 45 ± 2 mM-1cm-
1)47,54 and provides confirmation that Orf12 generated the same product as LmbB1. 
However, LmbB1 was reported earlier to form 2.1.48 This was based on a 1H NMR 
spectrum of an equal mixture of product and starting material for which the coupling 
constant (8 Hz) of a substrate signal (6.94 ppm) was erroneously assigned to the product 
and used incorrectly to rule out the formation of 1.1.48 A 1H NMR spectrum of the starting 
material confirms the reassignment (Appendix A-5). Conditions used to isolate the enzyme 
product did not appear to alter the cyclized structure. NMR analysis of the crude product 
confirmed the predominance of 1.1 rather than 2.1 despite the greater conjugation of 2.1. 
Differentiating between these tautomers is important to distinguish between potential 
substrates of the enzymes downstream in the biosynthetic pathways, particularly those of 





similarly generated during lincomycin A and hormaomycin biosynthesis as well. 
Equivalent ESI+-MS data were recorded for the product formed by both HrmF37 and Orf12. 
 Previously, a 2,3-extradiol dioxygenase involved in betalain biosynthesis in the 
fungus Amanita muscaria was reported to form the seven-membered ring, muscaflavin 
after formation of L-2,3-secodopa (Scheme 2-4).56 This raises the possibility of a pathway 
that is non-productive for PBD formation may act competitively during dihydropyrrole 
biosynthesis. However, only 1.1 was detected from cyclization of L-2,3-secodopa. A 
characteristic aldehydic signal expected in the 1H NMR spectrum of muscaflavin was not 
observed. The 1H NMR signals for the product assigned as 1.1 did not agree with the 
literature values reported for muscaflavin.56 This indicates that the intramolecular 
cyclization of L-2,3-secodopa to muscaflavin observed in betalain biosynthesis56 does not 
occur in PBD dihydropyrrole biosynthesis. It is unclear if Orf12 prevents this process, 
which had been described as spontaneous.56 
 The A. muscaria 2,3-extradiol dioxygenase is known to cleave at the alternative 
C4-C5 bond of L-DOPA to form betalamic acid via L-4,5-secodopa (Scheme 2-5).56  This 
suggests that the dioxygenases involved in PBD dihydropyrrole biosynthesis might have 
the potential to cleave the aromatic ring of L-DOPA at multiple sites. However, no products 
of Orf12 resulting from 4,5-cleavage of L-DOPA were observed as indicated by the absence 
of 1H NMR signals for the aldehydic protons of L-4,5-secodopa or betalamic acid. This 
indicates that Orf12 acts regiospecifically to cleave only the expected C2-C3 bond of L-
DOPA. Alternative cleavage to form L-4,5-secodopa and betalamic acid would have 




Scheme 2-5. PBD biosynthesis does not involve a competitive oxidation of L-DOPA to 
generate a non-productive derivative, betalamic acid. 
 
 Is L-2,3-secodopa a biosynthetic intermediate of PBD biosynthesis? The 
transient product observed by UV-visible spectroscopy during dioxygenation is consistent 
with L-2,3-secodopa since its absorbance maximum was similar to that exhibited by 2,3-
secocaffeic acid (Amax at 384 nm).48 The extra conjugation of this analog explains the red-
shift (16 nm) of its absorbance maximum relative to that of L-2,3-secodopa. UV-visible 
spectroscopy revealed that the equilibrium between 1.1 and the colorless compound L-2,3-
secodopa (Amax at 368 nm) can be shifted by increasingly acidic conditions (pH 3-5) 
(Appendix A-6). The absorbance maximum of L-2,3-secodopa was slightly lower than that 
implied during its formation by dioxygenation (Amax at 378 nm) of L-DOPA due to the 
additive effect of the absorbance from 1.1. The transient compound was verified to be L-
2,3-secodopa (ε368 nm = 27 ± 2 mM-1cm-1 at pH 4.0) by its ability to reconvert to 1.1 upon 
exposure to base (Appendix A-6) and by the presence of a downfield resonance (9.08 ppm) 
in its 1H NMR spectrum (Appendix A-7) that corresponded to its aldehydic proton. The 
assignment was further confirmed by the coupling constant (3JHH = 7.4 Hz) between vicinal 
protons H1 (6.01 ppm) and H2 (7.11 ppm) that is diagnostic of an anti-Karplus type 
arrangement of protons (3JHH expected = <11 Hz) found in L-2,3-secodopa and missing in 1.1. 
Partial degradation of L-2,3-secodopa occurred within the time (1 h) required for NMR 
characterization, as indicated by a decreasing signal at its maximal absorbance of 368 nm. 
22 
 
The degradation products likely contributed the small signals in the 1H NMR spectrum that 
remain unannotated. 
 The formation of L-2,3-secodopa catalyzed independently by Orf12 and SibV was 
consistent with the products generated by turnover of other 2,3-extradiol dioxygenases that 
cleave catechols to form acyclic 2,3-secocatechols.57 Further reaction of L-2,3-secodopa 
begins with condensation of the nucleophilic amine with the proximal aldehyde and 
subsequently undergoes dehydration to form the dihydropyrrole 1.1 (Scheme 2-6). This 
cyclization occurs spontaneously since its rate was shown by others to be independent of 
enzyme concentration in the LmbB1-dependent production of L-2,3-secodopa.54 Whether 
downstream biosynthetic enzyme(s) prefer the acyclic compound L-2,3-secodopa or the 
cyclic compound 1.1 as substrate is not yet known. 
 
 
Scheme 2-6. Orf12 and SibV catalyzed the dioxygenation of L-DOPA to form L-2,3-
secodopa, a transient species observed only within the first minute of dioxygenation at pH 
>8 before it cyclized spontaneously to 1.1. 
 
 The lifetime of L-2,3-secodopa at pH 8 (250 mM sodium phosphate) is unusually 
short for further processing by subsequent biosynthetic enzymes. Exposure to a basic 
environment slows the cyclization of L-2,3-secodopa54 suggesting that dioxygenation 
reactions performed at pH > 8 may shift the equilibrium from 1.1 to L-2,3-secodopa. To 
assess the effect of increasing basicity on the equilibrium between L-2,3-secodopa and 1.1, 
the cleavage of L-DOPA by either SibV or Orf12 was performed over a range of pH 
conditions (Figure 2-1 and Appendix A-3 and A-8). Not surprisingly, L-2,3-secodopa 
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formed too transiently to be observed under neutral (pH 7) or slightly acidic conditions (pH 
6). In contrast, L-2,3-secodopa persisted longer when it formed at pH 9 (Amax at 378 nm 
disappeared within 80 sec) rather than at pH 8 (Amax at 378 nm disappeared within 40 sec). 
However, the transiency of L-2,3-secodopa even at pH 9 suggests that 1.1 is the only 
candidate that would persist long enough for further processing during assembly of the 
PBD dihydropyrrole moiety. 
 Lifetime of 1.1. The lability and non-enzymatic degradation of 1.1 was apparent 
from the decrease of its absorbance at 414 nm over hours (Appendix A-9). At pH 8.0, its 
half-life was approximately 36 h at 25 °C and 25 h at 37 °C. A 1H NMR spectrum of the 
final degradation mixture showed a new downfield singlet (8.91 ppm) corresponding to an 
aldehydic proton but there were also at least another 16 new signals that could not be 
definitely assigned to any mixture of aldehyde containing isomers of 1.1 (muscaflavin, L-
4,5-secodopa or betalamic acid). The instability of 1.1 may also arise from its tendency to 
polymerize via nucleophilic addition at the α,β-unsaturated γ-keto acid. The observed 
lability of 1.1 suggests that the efficiency of the next enzyme in the biosynthetic pathway 
that consumes it is an important property to consider when manipulating this pathway in 
the future for engineering new PBD derivatives. 
2.3 Summary 
 The dioxygenases Orf12 and SibV associated with the biosynthesis of PBDs were 
shown to catalyze the cleavage of the aromatic ring in L-DOPA to form L-2,3-secodopa. 
This compound in turn spontaneously cyclized to 1.1 verified by 1H NMR spectroscopy. 
Together, these processes are crucial for generating the scaffold of the dihydropyrrole 
moiety common to all PBDs. The oligomeric state and enzymatic product generated by the 
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dioxygenases Orf12, SibV, LmbB1 and HrmF are conserved in the formation of PBDs, 
lincomycin A and hormaomycin. These observations suggest a likely commonality in all 
dihydropyrrole and pyrrolidine biosynthetic pathways originating from L-tyrosine. 
2.4 Experimental Procedures 
 Materials. The pET28b plasmid and electrocompetent BL21(DE3) strain were 
obtained from Novagen (Darmstadt, Germany). The pSMT plasmid and Ulp1 expression 
vector were generously donated by Dr. C. Lima at the Sloan Kettering Institute (New York, 
NY).49 Electrocompetent strain of GeneHogs E. coli was obtained from Invitrogen 
(Carlsbad, CA). Ni-NTA agarose was obtained from Qiagen (Valencia, CA). Sephacryl S-
200 HR and a gel filtration calibration kit containing low molecular weight standards were 
obtained from GE Healthcare (Piscataway, NJ). An Econo-Pac 10DG column prepacked 
with Bio-Gel P-6DG gel was obtained from Bio-Rad (Hercules, CA). The Coomassie 
Brilliant Blue R-250 protein stain powder was obtained from Bio-Rad (Hercules, CA). L-
DOPA was obtained from Sigma (St. Louis, MO). H2O was purified to a resistivity of 18.2 
Ω-cm. All other reagents were purchased at the highest grade commercially available and 
used without further purification. 
General methods. Protein purification was performed using an ÄKTA Prime 
Liquid Chromatography from GE Healthcare. Protein samples were analyzed by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) made with 12% 
resolving and 4% stacking acrylamide layers. Protein samples were visualized after SDS-
PAGE by staining the gel with Coomassie Brilliant Blue R-250. Protein concentrations 
were calculated using extinction coefficients (ε) at 280 nm predicted by ExPASy 
ProtParam.58 All UV-visible absorption spectra were obtained using a Varian 
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monochromator UV-visible Cary 100 Spectrophotometer (Walnut Creek, CA). 1H NMR 
experiments were performed on a Bruker 500 MHz with H2O suppression using a 
presaturation pulse sequence and COSY experiments were performed on a Bruker 400 
MHz with H2O suppression.59 Chemical shifts (δ) and coupling constants (J) are reported 
in parts per million (ppm) and Hertz (Hz), respectively. Mass spectra were obtained in the 
ESI+ mode using a Waters Acquity UPLC-Xevo-G2-Q-Tof-MS (Milford, MA) equipped 
with a 2.1 mm x 50 mm BEH-C18 column (1.7 µM and 300 Å pore size) using a 0-80% 
aqueous acetonitrile gradient over 12 min (0.3 mL/min). Quaternary structure was 
characterized with a gel filtration column (Superdex 200 HR 10/3) generously provided by 
Dr. Z. Kelman formerly at University of Maryland Biotechnology Institute (UMBI) 
(Rockville, MD). Dihedral angles were predicted by Chem3D Pro 13.0.2 from PerkinElmer 
(Waltham, MA). All assays were performed at 25 °C unless stated otherwise. All plasmid 
constructs were confirmed by sequencing (UMBI). 
 Expression of apo-dioxygenases. BL21(DE3) starter cultures, transformed with 
either pSMT3/sibV or pET28b/orf12,60 were diluted 200-fold in Miller LB broth 
supplemented with kanamycin (50 µg/mL) and grown at 37 °C with agitation until the 
OD600 nm reached 0.9. The cell cultures were then induced with D-lactose (0.2%) at 30 °C 
with agitation (12 h), harvested by centrifugation at 5,000 rpm at 4 °C (15 min) and flash 
frozen in N2 (l) for storage at -80 °C. 
 Purification of apo-dioxygenases. All purification steps were performed at 4 °C. 
Cells alternatively expressing His6-Orf12 or His6-SUMO-SibV were resuspended in wash 
buffer (50 mM sodium phosphate pH 8.0, 300 mM NaCl, 1 mM fresh DTT and 20 mM 
imidazole). Protease inhibitors benzamidine (1 mM) and phenylmethylsulfonyl fluoride (1 
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mM) were added and then the cells were lysed by four passages through a French Press at 
1,000 psi. Cell debris was removed by centrifugation at 15,000 rpm (30 min) and the 
supernatant was loaded onto a Ni-NTA agarose (11 mL) column pre-equilibrated with 
wash buffer. The resin was washed with wash buffer and the dioxygenase was eluted with 
elution buffer (50 mM sodium phosphate pH 8.0, 300 mM NaCl, 1 mM fresh DTT and 250 
mM imidazole) at 1 mL/min. The SibV fusion underwent additional steps to remove the 
SUMO tag via proteolysis by adding Ulp1 (1:100 w/w) to the eluate for 12 h.  The digestion 
was dialyzed (2 x 1 L) (12-14 kDa MWCO) against wash buffer, reapplied to the Ni-NTA 
agarose column pre-equilibrated with wash buffer and eluted with wash buffer. His6-Orf12 
and SibV were then separately dialyzed (2 x 1 L) against gel filtration buffer (50 mM 
sodium phosphate pH 8.0, 10% glycerol and 1 mM fresh DTT), concentrated in a 
pressurized stirred cell (10,000 NMWL) (EMD Millipore) under N2 (g) (40 bars) to a 
volume of 600 µL and applied onto a Sephacryl S-200 HR column (254 mL) pre-
equilibrated with gel filtration buffer. The dioxygenases were then eluted with gel filtration 
buffer at 0.4 mL/min. The resulting apo-dioxygenases were ≥ 95% pure as estimated by 
ImageQuant analysis after their separation by denaturing gel electrophoresis and staining 
with Coomassie Brilliant Blue. Enzyme solutions in gel filtration buffer were flash frozen 
in droplets with N2 (l) and stored at -80 °C until needed. 
 Reconstitution of apo-dioxygenases with Fe2+. Each apo-dioxygenases (3.2 mM) 
was reconstituted in gel filtration buffer with FeSO4·7H2O (2.5 mM) in the presence of 
DTT (15.6 mM) and L-ascorbic acid (sodium salt, 15.6 mM) for 25 min at 4 °C producing 
red solutions. The reconstituting agents were removed via buffer exchange into desalting 
buffer (100 mM sodium phosphate pH 8.0) with a P-6DG desalting column (10 mL) pre-
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equilibrated with desalting buffer. The resulting light blue holo-dioxygenases solutions in 
desalting buffer were flash frozen in droplets with N2 (l) and stored at -80 °C. The holo-
dioxygenases used for assays were subjected to a maximum of one freeze and thaw cycle. 
 Determination of the oligomeric state of SibV. Ribonuclease A (13.7 kDa), 
ovalbumin (44.0 kDa), conalbumin (75.0 kDa) and aldolase (158.0 kDa) were used as 
molecular weight standards and blue dextran (2,000.0 kDa) was used to determine the void 
volume (Vo). The molecular weight standards and holo-SibV (20 µg) were individually 
dissolved in size exclusion buffer (50 mM sodium phosphate pH 8.0, 150 mM NaCl, and 
1 mM fresh DTT) and loaded onto the Superdex-200 resin column that had been pre-
equilibrated with size exclusion buffer. Each sample was eluted with size exclusion buffer 
at 0.4 mL/min at 4 °C. The partition coefficient (Kav) was calculated (Equation 2-1) using 
elution volume (Ve), Vo, and packed resin volume (Vc). A calibration curve was generated 
by plotting Kav against the log of the molecular weight (MR). 
Equation 2-1.                            Kav = (Ve - Vo) / (Vc - Vo) 
 Generation and purification of the product 1.1 formed by Orf12. Freshly 
thawed holo-Orf12 (0.4 mM) was added in aliquots (44) every 30 sec to a solution of L-
DOPA (17.7 mM) in sodium phosphate (30 mM, pH 8.0). The enzyme was precipitated by 
washing the reaction mixture with chloroform (3 x 3 mL). Residual chloroform was 
removed from the aqueous layer under reduced pressure for 20 min to yield a yellow 
solution. Compound 1.1: 1H NMR (10% D2O, 500 MHz) δ 7.59 ppm (s, 1H), 7.58 ppm (d, 
J = 16 Hz, 1H), 5.52 ppm (d, J = 16 Hz, 0.5H), 4.59 ppm (dd, J = 6.2, 12 Hz, 0.8H), 3.11 
ppm (dd, J = 12, 16 Hz, 1H), 2.72 ppm (dd, J = 6.2, 16 Hz, 1H). ESI+-MS: m/z 212.06 
(M)+, 166.05, 148.04. 
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 Acid-catalyzed hydrolysis of 1.1 to form L-2,3-secodopa. A solution of 1.1 (13 
mM) in sodium phosphate (20 mM, pH 8.0) was spiked with deuterium chloride (DCl) 
(1.6% v/v) to form L-2,3-secodopa. 1H NMR (10% D2O, 400 MHz) δ 9.08 ppm (s, 1H), 
7.11 ppm (d, J = 7.4 Hz, 1H), 6.01 ppm (d, J = 7.4 Hz, 1H), 3.44 ppm (m, 2H), 2.34 ppm 
(d, J = 15 Hz, 1H). 
 Determination of extinction coefficients for 1.1 and L-2,3-secodopa. A fixed 
concentration of L-DOPA (7.6 mM) determined spectrophotometrically (ε280 nm = 2.53 mM-
1cm-1)61 was transformed into 1.1 by batchwise addition of holo-Orf12 (0.2 mM) described 
above. 1H NMR analysis confirmed full conversion to 1.1 based on the lack of signals 
associated with L-DOPA. The absorbance of 1.1 at 414 nm was measured at pH 8.0 and 
Beer’s law was used to calculate the ε414 nm of 1.1. A fixed concentration of 1.1 (15 µM) 
determined spectrophotometrically was then transformed into L-2,3-secodopa with acid (a 
1000-fold scaled down version of the procedure described above). Disappearance of an 
absorbance maximum at 414 nm and appearance of an absorbance maximum at 368 nm 
confirmed full conversion to L-2,3-secodopa. The ε368 nm of L-2,3-secodopa was back-
calculated at pH 4.0 using the ε414 nm of 1.1 and the absorbance values at those respective 
wavelengths for both compounds (15 µM). These studies were done in triplicate and the 







Chapter 3: Probing the Roles of SibS and SibZ 
 
3.1 Introduction 
Upon formation of the dihydropyrrole 1.1, a hydrolysis and a methylation step were 
proposed to modify its exocyclic carbon chain as the next steps in the biosynthetic pathway 
(Scheme 3-1).23 The hydrolysis step that removes two-carbon units from 1.1 was proposed 
to rationalize why PBD producers incorporated only seven out of the nine radiolabeled 
carbons from either [14C]-L-tyrosine or [14C]-L-DOPA into the PBD dihydropyrrole moiety 
(Scheme 1-6).30 The methylation step was used to explain why the third terminal carbon 
in the exocyclic chain in the final moiety originates from the methyl carbon in L-methionine 
(Scheme 1-6).30 L-methionine is a precursor of the biological methylating agent SAM. 
These two modifications could form 1.3, a biosynthetic intermediate generated by a strain 
of the lincomycin A producer mutated to incapacitate synthesis of the F420 cofactor and 
prevent formation of 1.4.31,32,42 The F420 cofactor is a deazariboflavin derivative involved 
in redox reactions. The mutant study suggests that the hydrolysis and methylation steps 
precede the F420-dependent reduction step. Subsequent steps were proposed to impart the 
structural diversity observed among the dihydropyrrole and pyrrolidine moieties unique to 
each producer.2,33 
The hydrolysis and reduction reactions expected to be common to the biosynthesis 
of the dihydropyrrole and pyrrolidine moiety are logically catalyzed by enzymes conserved 
throughout the pathways. The sibiromycin gene cluster contains two genes (sibT and sibY) 
that have orthologs in PBD, lincomycin A and hormaomycin gene clusters.2 Both of these 




Scheme 3-1. Biosynthetic steps proposed to modify the exocyclic carbon chain in the 
dihydropyrrole 1.1 to form sibiromycin, representative of transformations predicted 
throughout the syntheses of other PBDs as well as lincomycin A and hormaomycin. 
 
analysis.31 SibT, encoded by the sibT gene, contains a domain in its predicted amino acid 
sequence characteristic of F420-dependent oxidoreductases (expect value of 10-33).31 SibY, 
encoded by the sibY gene, belongs to the γ-glutamyltranspeptide superfamily according to 
BLAST analysis (domain hits with expect values from 10-39 to 10-144).31 It is proposed that 
SibY conjugates the requisite number of glutamyl residues onto the F420 cofactor to bind 
SibT allowing the cofactor to provide the hydride necessary for reducing 1.3.31 
Surprisingly no other gene is conserved throughout the PBD, lincomycin A and 
hormaomycin biosynthetic pathways, making it difficult to assign a gene product that 
catalyzes the hydrolysis of 1.1 to 1.2. The sibS gene in the sibiromycin gene cluster is 
conserved throughout the other gene clusters except in hormaomycin’s. Assuming another 
gene codes for the hydrolase used in hormaomycin biosynthesis, sibS was tentatively 
proposed to code for the hydrolase (SibS).31 SibS shares sequence homology mostly with 
uncharacterized proteins, low (21%) sequence homology with the isomerase PhzF62,63 and 
no sequence homology to known lyases according to BLAST analysis. However, the 
biosynthesis of the dihydropyrrole moiety appears to require SibS. A knockout of the sibS 
gene64 prevented the production of sibiromycin in the resulting mutant S. sibiricum strain. 
The analogous knockout of the sibS ortholog lmbX resulted in a mutant S. lincolnensis 
strain incapable of producing lincomycin A without the addition of exogenous 4-
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propylproline, a precursor of its pyrrolidine moiety.65 The gene knockout and rescue 
studies indicate that SibS is essential in the biosynthesis of sibiromycin’s dihydropyrrole 
moiety. The means by which the two terminal carbons from 1.1 are removed during 
hormaomycin biosynthesis is unclear, since no sibS ortholog could be located in its 
corresponding gene cluster or elsewhere on the genome using Southern hybridization and 
degenerate PCR.37 
The methylation reaction is expected to be common throughout the pathways 
except in tomaymycin that lacks one carbon common to the other PBDs, lincomycin A and 
hormaomycin. The sibZ gene from the sibiromycin gene cluster is proposed to code for the 
methyltransferase (SibZ) based on the presence of a SAM binding motif 
(AGCGCGQx17DNx25ADAx17I) in the predicted amino acid sequence according to 
BLAST analysis. This assignment is further supported by the conservation of SibZ 
homologs throughout the pathways except tomamycin’s.31-33 
SibS and its homologs are tentatively proposed to hydrolyze 1.1 to 1.2 while SibZ 
and its homologs are expected to methylate 1.2 to 1.3 to continue the biosynthesis of the 
dihydropyrrole moiety (Scheme 2-4). To confirm the functional assignment of these 
proteins, SibS and SibZ were produced and treated with their expected substrates. As these 
transformations are expected to be common to other dihydropyrrole moiety biosyntheses, 
the SibS homolog in tomaymycin (TomK) was also produced and similarly tested. 
3.2 Results and Discussion 
Production of SibS, TomK and SibZ. SibZ expression and purification followed 
the cloning of the sibZ gene into the BamHI and HindIII sites of the pSMT3 vector. The 
equivalent vectors containing the sibS66 and tomK67 genes were already available. Each 
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was expressed in E. coli as His6-SUMO fusion proteins and purified via Ni-NTA and size 
exclusion chromatography in a manner similar to the purification of SibV (Chapter 2). The 
final purification step provided ca. 11 mg SibS, 3 mg TomK and 4 mg SibZ per liter of 
growth media (Appendix B-1). 
SibS and TomK treatment with 1.1. SibS was incubated with 1.1 and assayed for 
the hydrolysis product 1.2 (Scheme 3-2). UV-visible absorbance spectra of the 1.1 (20 µM) 
with and without SibS (1 µM) were monitored hourly up to 24 h. Formation of the catalytic 
product 1.2 was expected to be accompanied by an increase in absorbance at a wavelength 
lower than that of 1.1 (414 nm) since the product is less conjugated than the substrate. 
However, no new signal was observed suggesting hydrolysis to remove the α-keto acid 
from 1.1 did not occur. The absorbance maximum at 414 nm diminished over time for both 
the reaction and the negative control consistent with non-enzymatic decomposition of the 
substrate observed in Chapter 2. 
 
Scheme 3-2. SibS and TomK were expected to catalyze the hydrolysis of 1.1 into 1.2 and 
oxalate as part of sibiromycin and tomaymycin biosynthesis, respectively.31, 32 
 
Since hydrolysis was expected to form oxalate as the second product, a coupled 
enzyme assay68 that detects oxalate was used as well to monitor the reaction (Scheme 3-
3). The assay relies on oxidizing oxalate to form hydrogen peroxide that is, in turn, 
converted to indamine. Indamine is a purple dye that can be detected 
spectrophotometrically (Amax = 600 nm). An aliquot of the reaction mixture containing 1.1 
(1 mM) and SibS (1 µM) was subjected to the coupling enzyme assay and compared with 
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an equivalent reaction mixture without SibS. The absorbance intensities at 600 nm were 
the same for both reactions suggesting the expected hydrolysis did not occur and produce 
oxalate. However, a positive control indicates that oxalate could only be detected in 
equivalent reactions spiked with at least 20 µM oxalate. Substrate turnover of at least 2% 
was necessary to obtain a detectable signal. 
 
 
Scheme 3-3. Coupled enzyme assay to indirectly detect formation of oxalate. 
 
Reaction mixtures with and without SibS were also subjected to separation by 
HPLC but their chromatograms appeared to be identical again suggesting no hydrolysis 
occurred (Figure 3-1). To verify that no unexpected proteolysis occurred during the 
purification of SibS to prevent activity, the mass of purified SibS was verified. SibS had a 
parent ion experimental mass of 30790.95 Da in agreement with its theoretical mass of 
30790.89 Da within a mass deviation of 1.9 ppm. Replacing SibS with homolog TomK did 
not change the results indicating the inactivity observed under the assay conditions is not 
unique to sibiromycin biosynthesis. 
Hydrolysis of 1.1 was expected to involve an initial tautomerization, a step 
observed during the hydrolysis of another α-keto acid substrate between a carbon-carbon 
bond by another hydrolase (BphD)69 (Scheme 3-4). The assays described above (UV-

































Figure 3-1. HPLC chromatogram (blue) monitoring SibS incubated with of 1.1 (tr = 4.9 
min) expected to form 1.2 and oxalate upon hydrolysis. The reaction mixture was quenched 
at 4 h and subjected to HPLC separation. The additional chromatogram (red) depicts an 
equivalent reaction mixture lacking SibS as a negative control. 
 
tautomerization of 1.1. Thus a reaction mixture of SibS with 1.1 was additionally 
monitored by 1H NMR spectroscopy to detect the disappearance of vicinal coupling 
between H1 and H2 characteristic of the tautomer 1.1 as described in Chapter 2 and for the 
appearance of a methylene signal H1 upon tautomerization to the imine. However, all 
changes in proton signals observed over 24 h were also present in the spectrum of the 
equivalent reaction without SibS. These changes corresponded to the non-enzymatic 
degradation of 1.1 addressed in Chapter 2. SibS did not appear to catalyze tautomerization 
or hydrolysis of 1.1 under the assay conditions. Replacing SibS with TomK produced 
identical results. 
The addition of a metal cofactor may be indispensable for catalytic activity as 
observed with other hydrolases.70 The divalent metal cation may act as a Lewis acid to 
coordinate the carbonyl oxygen and reduce the pKa of H2O to generate the hydroxide 




Scheme 3-4. A possible mechanism of SibS or TomK catalyzed hydrolysis of 1.1 initiates 
with a tautomerization step, in analogy to the mechanism of another hydrolase (BphD) that 
hydrolyzes a carbon-carbon bond of another α-keto acid substrate.69 
 
tetrahedral intermediate before breaking down into 1.2 and oxalate (Scheme 3-5). To test 
the requirement of divalent metal cation, Mg2+, Zn2+ and Mn2+ capable of promoting 
activity of other hydrolases70 were considered. The reaction mixtures containing 1.1 (1 
mM) with and without SibS (1 µM) were incubated with a divalent metal cation (1 mM). 
However, neither oxalate not 1.2 was detected using the oxalate and HPLC assay described 
above. 
 
Scheme 3-5. Potential role of a divalent metal cation to facilitate hydrolysis of 1.1. 
 
Binding of SibS with 1.1. The inability of SibS to process 1.1 suggests that the 
putative substrate and role of SibS was incorrect. Since an enzyme-catalyzed reaction with 
its substrate entails binding the substrate prior to its turnover, it was instructive to determine 
if SibS had any affinity for 1.1. Low affinity (> 1 mM) would further support a revision of 
SibS’s role and substrate in the biosynthesis of sibiromycin. A decrease in the intrinsic 
fluorescence of SibS was observed during titration of 1.1 and consistent with 1.1 binding 
SibS to quench the fluorescence signal. The decrease in fluorescence intensity was used to 
fit for the dissociation constant (KD = 64 ± 2 µM) assuming a simple binding process.71 
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The ability of SibS to bind 1.1 suggests either SibS catalyzes a reaction with 1.1 but 
requires an unidentified cofactor or protein partner or 1.1 is structurally similar to the actual 




Figure 3-2. Intrinsic fluorescence quenching of SibS (3 µM) by 1.1. Fluorescence emission 
intensity (λem of 340 nm, λex of 290 nm) was measured during titration in 20 mM sodium 
phosphate pH 8.0 (25 °C). The fractional saturation (Ῡ) was calculated and the data was fit 
to an analysis described in the Experimental Procedures. 
 
Crystal structure of SibS with 1.1. SibS belongs to the DAP epimerase 
superfamily according BLAST analysis. The substrate and function of most members of 
this superfamily have not been identified with a few exceptions known to catalyze 
prototropic shifts.72 Among these, PhzF62,63 is structurally related` to SibS73 according to 
the superposition of their respective crystal structures (RMSD of 5.2 Å) (Figure 3-3). The 
active site for SibS was tentatively assigned at the interface of two subdomains from each 
monomer based on its location in the PhzF dimer. The oligomeric state of SibS was 
examined by gel filtration and appears to form a dimer in solution (observed molecular 









ProtParam). Despite the structural similarity of SibS and PhzF, their sequence identity is 
low (21%) suggesting functional divergence between these enzymes. A crystal structure of 
SibS in complex with 1.1 could provide more information on the tentative active site. 
Specifically, this includes identifying residues that coordinate 1.1 to check if they are 
conserved in other members of the superfamily for binding and catalysis. 
A                                                                     B 
 
 
Figure 3-3. A. DAP-epimerase superfamily member PhzF catalyzes a pericyclic 
prototrophic shift followed by enol-keto tautomerization. B. Superimposed crystal 
structures of two SibS monomers, depicted in brown, obtained at 2.2 Å resolution and PhzF 
homodimer, depicted in green, with an RMSD of 5.2 Å based on an overlap of 462 Cα 
atoms in 598 total amino acids. 
 
SibS crystals were transferred by Dr. Chuenchor into a soaking solution (1 mM 
DTT, 75 mM HEPES pH 7.5, 1.4 mM lithium sulfate and 15% glycerol) containing the 
ligand 1.1 (4.7 mM) for three hours. X-ray diffraction data was collected and processed by 
Dr. Chuenchor. Ligand density was observed at the proposed active site although it could 
not be refined to 1.1 (Figure 3-4) suggesting the ligand is dynamic. Instead, water 
molecules were built into the density of the ligand in order to identify the residues in 
proximity of the ligand. 
The ligand coordinates to a catalytic residue conserved in DapF74 and substrate 
binding residues conserved in PhzF62,63 representing a new active site architecture in the 
DAP epimerase superfamily. Specifically, the ligand coordinates to C213 conserved in and 




Figure 3-4. Schematic view of the SibS-1.1 complex. 
D210 that is conserved in PhzF. They are substrate binding residues, the latter of which is 
also essential for activating the substrate for PhzF prior to turnover. These residues are 
conserved in the predicted amino acid sequences of SibS homologs involved in the 
production of other dihydropyrrole and pyrrolidine moieties (Figure 3-5). They are also 
conserved in the amino acid sequence of a eukaryotic member of the superfamily (Aes1) 
although its substrate and biochemical function have yet to be identified.75 Additional 
aromatic residues (Y73 and W205), a pair of glycines (G74 and G75) and A202 in SibS 
coordinate the ligand as well. These coordinating residues are conserved or mutated 
conservatively in the homologs except for G75. This glycine is replaced with a threonine 
in the homolog associated with anthramycin and porothramycin biosyntheses. The 
functional consequence of this new type of active site is unknown. 
Synthesis of SibZ’s putative substrate 1.2. SibS treatment of 1.1 did not form 1.2, 
the proposed substrate for SibZ. If SibS requires an unidentified cofactor or protein partner 
to catalyze hydrolysis, the remaining part of the proposed pathway could still be correct. 
In order to test if SibZ catalyzes the SAM-dependent methylation of 1.2, the proposed 
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TomK        --MIAYEIVDMFTDTPYGGCALGVVPDAAALSTADMLAVARETALT----ETAFVVPPAL 54 
SibS        -MTVSFEIVGIFGTEPGGGSPLAVVHDAGGLSTEQMRWIAGRLRAD----ETVFVLPPAT 55 
Orf15       ---MRVTTVDMFGAAPGRGSALDVLVPDGPCGEAAAEEAAAHARRS-AADESVLVVECRR 56 
Por16       -----MTRVDMFGTAPGRGAALDVLVPEGPRADDAVAHAAAHARTTDDTVESALVSECSR 55 
LmbX        MIVVPFEMVDMFAHEPFSGSQLTVVPDADGLTDAAMEALAREVNTP----ETAFVLPPAD 56 
Aes1        MTEHSFKQIDVFSNKGFRGNPVAVFFDADNLSQKEMQQIAKWTNLS----ETTFVQKPTI 56 
                    :.:*      *  : *.              *          *:.:*      
 
                          ▲     ▲ 
TomK        PGSTYGVRVMTPDGESPYGGHSAVGTASALVRAGRLAAG--EAVQECGGRQLAVTAGA-- 110 
SibS        SGATYRVRVFTAAGESPYGGHSAVGTAVSLVRRGDIRPG--TVVQECGGRQLTLRAGA-- 111 
Orf15       AQRTFASRVFNAGGETPFATHSLAGAAACLVGAGHLPPG--EVGRTAESGSQWLWTDG-- 112 
Por16       QQRTFASRIFNTGGETPFGTHSLAGVAALLVSRGHLDPG--EVGRKSDAGCQWLRTDG-- 111 
LmbX        PGATYRVRVFTLAGETPFGGHSSLGTAVTLVRLGRVAPG--AVAQECGSRLHSLSVGP-- 112 
Aes1        DKADYRLRIFTPECELSFAGHPTIGSCFAVVESGYCTPKNCKIIQECLAGLVELTIDGEK 116 
                :  *::.   * .:. *.  * .  :*  *   .      : . .    :  .    
 
TomK        DGSTLSVAGEPLLRPEWDPGPLLTACGLTD-----TDLTGTP-RLTGFGPAFHVLPVG-- 162 
SibS        DRAEFAATGTPRVESLP-ADPVLDAIGLAA-----ADLAGEP-VLAGFGPLFRMVPVR-- 162 
Orf15       HEVRVPFDGPVVHRGIPHDPALFGPY------------AGTP-YAGGVGRAFNLLRVA-- 157 
Por16       REVEVPFSGPVVDHEIPADPALFGSY------------DGTP-RASGVGRAFTILRVS-- 156 
LmbX        DKGTVT-AEKPVEAREPDLRLLTAAAGVDP-----ADVVEAPVRTAGFGPAFHYLQVR-- 164 
Aes1        DEDTWISFKLPYYKILQTSETAISEVENALGIPLNYSSQVSPPVLIDDGPKWLVIQLPNA 176 
                                                     *    . *  :  : :    
 
                                                              ▲  ♦ 
TomK        ---AKALTRAAADLTDPVWADCPDAVLVAWDQAGRTARVRVFAPGYGMPEDPACASAALG 219 
SibS        ---QEALGRARPDFPAMTRHELPEIFLFAWDGPAASAEARLFAPGWAIPRDPACASVALA 219 
Orf15       ---EDPRTLPAPDPGRMRELGFTDLTVFRWDPDRGEVLARVFAPGFGIPEDAGCLPAAAA 214 
Por16       ---DDPRALPVPDAKRMADLGLTDLTLFRWDPDNREVLARVFAPGFGLPEDPGCLPAASA 213 
LmbX        ---EGVVPGARADLELMARRDLPDVMVFSWDPRTRQATARVFAPGYGMPEDPACASNALG 221 
Aes1        TDVLNLVPKFQSLSQVCKNNDWIGVTVFG-ELGKDSFESRSFAPLIHVNEDPACGSGAGA 235 
                       .              :.  :        * ***   : .*..* . * . 
 
TomK        LGAWLAEEKALPGADGRHAYQVRQGEGLGRPATLSCTVDLTGG-RATAATVHGRVTLTAS 278 
SibS        FGAWLADRQGRP--DAPRPFLIRQGAELGRPALLSGTLGAGSGDAEITVTVGGPAPGELA 277 
Orf15       LG--VAALRLAA--DDRTSVTVRQVTVRGTESVFRCTGSARGG--SANVTITGRVWTGG- 267 
Por16       LG--LTALALTAPGDREEPVTIRQVTGNGTESVLRCTGSVHDG--AAQVRVTARVWADGD 269 
LmbX        LGEWLVAAGRLPAADGTYEYLIRQGVGSPRVGTVECSVTVDSG-CAVRASATGSVVPVAR 280 
Aes1        VGVYIGSSQKTP---TSLSFTISQGTKLSRQAISKVSVDVSSN-KSIAVFVGGQAKTCIS 291 
            .*  :      .         : *       .    :    ..     .   . .      
 
TomK        GRMTP-PGRP------------ 287 
SibS        GQITASPPDASQPNVLRTSSAA 299 
Orf15       ---TAGREVGGS---------- 276 
Por16       RVWAEGDRVRADGDRKARTG-- 289 
LmbX        GEFLLGPDLATAVASV------ 296 
Aes1        GKSFI----------------- 296 
 
Figure 3-5. Sequence alignment of SibS with related proteins. The proposed binding and 
catalytic residues in SibS and its homologs based on the crystal structure of SibS in 
complex with 1.1 are highlighted. These residues include ones that are conserved in DAP 
epimerase superfamily members PhzF and DapF involved in binding (denoted with ▲) and 
catalyzing (denoted with ♦) their substrates, respectively. The alignment includes Aes1 
(Schizosaccharomyces pombe) a eukaryotic member of the same superfamily with similar 




substrate was synthesized (Scheme 3-6). Briefly, enolization and triflation of 3.1 formed 
3.2. The enol triflate 3.2 was cross-coupled with tributytin-vinyl to install a vinyl group 
generating 3.3. 3.3 was demethylated and deprotected to form the desired compound 1.2. 
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Scheme 3-6. Scheme for synthesizing 1.2. 
 A pair of enol triflates formed during triflation as the starting material 3.1 
possessed two sets of enolizable protons. This was consistent with observation of a 
duplicate set of signals by NMR spectroscopy (Appendix B-2). A 1H NMR spectrum of 
the starting material 3.1 coincidentally contained two sets of signals but these coalesced at 
a higher temperature (40 °C) suggesting the convergence of cis and trans amides into one 
rotamer. The isomers persisted through Stille cross-coupling (Appendix B-4) and 
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demethylation (Appendix B-6). In contrast, the last step produced only the desired isomer 
(Appendix B-8). The extended conjugated π-π system in 1.2 likely provides the driving 
force that fortuitously converts the undesired isomer to 1.2 instead of 1.2’ (Scheme 3-7). 
The removal of the electron withdrawing carbonyl group after boc deprotection allows the 
lone pair of electrons on the nitrogen to extend the conjugation formed between the vinyl 
and ring double bonds, an option only available in the desired isomer 1.2. 
 
Scheme 3-7. Comparison of the conjugated π-π system in 1.2’ and 1.2 illustrated in red 
and blue, respectively. 
 
The structures drawn throughout the synthetic scheme are consistent with NMR 
spectra (1H, 13C, COSY, HSQC, HMBC) and MS (Appendix B-3, B-5, B-7, B-9) with the 
following exceptions. The amide carbonyl carbon signal (by 13C NMR) and the C2-C4 
correlation (by HMBC) were not observed in any of the compounds, a common issue with 
quaternary carbons. Two cross-peaks (H3-H7 and H5-H7) observed by NOESY 
(Appendix B-8) indicates that the product 1.2 was a mixture of geometric isomers 
(Scheme 3-8). This facile interconversion results from rotation around the single bond in 
the 1,3-butadiene group within 1.2. For comparison, 1,3-butadiene has a rotational barrier 
of 5 kcal/mol at room temperature.78 
 
 
Scheme 3-8. Two cross-peaks observed by NOESY consistent with the presence of 




SibZ treatment with 1.2. SibZ (1 µM) was treated with 1.2 (86 µM) and SAM 
(166 µM) and assayed for methylation to 1.3 (Scheme 3-9). An HPLC based activity assay 
was used to monitor the formation of SAH, one of the expected products of the methylation 
of 1.2 where SAM acts as a methyl donor (Scheme 3-9). The reaction mixture was 
separated by HPLC for analysis at various times up to 24 h. The HPLC chromatograms 
each produced a signal (tr = 13 min) corresponding to SAH (Figure 3-5). However, the 
signal integrated to a value equivalent to that of the corresponding signal produced by an 
equivalent reaction mixture without SibZ. This suggests that SibZ does not catalyze the 
methylation of 1.2 at rates above the control. A reaction mixture was spiked with SAH (86 
µM) at the beginning of the reaction to indicate that it did not decompose over 24 h and 
could be detected via HPLC analysis. 
 
Scheme 3-9. SibZ was expected to catalyze the methylation of 1.2 using SAM into 1.3 and 
SAH as part of sibiromycin biosynthesis.31,32 
 
The addition of a metal cofactor may be required for catalytic activity. Many SAM-
dependent methyltransferases use Mg2+ as a cofactor to enhance methylation activity 
including one enzyme that methylates an α-keto acid substrate.79 The reaction mixtures for 
SibZ were repeated in the presence of Mg2+ (1 mM). However, HPLC analysis of the 
reaction mixtures again indicated that methylation did not occur at rates greater than the 
controls. 
SibZ activity in the absence and presence of SibS. SibZ was unable to process 






Figure 3-6. HPLC chromatogram monitoring SibZ-incubated with 1.2 and the methyl 
donor SAM (tr = 8.7 min) expected to form 1.3 and SAH (tr = 13.1 min) upon methylation. 
The reaction mixture was quenched at various times and subjected to HPLC separation. 
Chromatograms detected at 254 nm are shown. The back chromatogram depicts an 
equivalent reaction mixture spiked with SAH and incubated for 24 h as a positive control. 
 
the substrate for SibZ.  The four precursors of 1.2 (L-tyrosine, L-DOPA, L-2,3-secodopa, 
1.1) were tested as substrates. L-2,3-secodopa was generated in situ via SibV-catalyzed 
dioxygenation of L-DOPA. HPLC separation of each reaction mixture indicates a small 
signal for the product SAH. However, an equivalent signal was detected during the HPLC 
separation of an equivalent reaction mixture without SibZ. This indicates that the putative 
substrates failed to undergo methylation at rates greater than the controls. 
The inactivity of both SibS and SibZ suggested each protein may require the other 
protein to form a functionally competent complex. Addition of SibS to the reaction mixture 
was analyzed by HPLC but did not appear to increase the SAH signal when compared with 
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Unexpected ability of SibS to depurinate SAM. The aforementioned studies that 
involved both SibS and SAM in the reaction mixture did produce a new compound detected 
by HPLC. Mixtures containing only SibS and SAM in buffer were monitored over time by 
HPLC and showed a time-dependent increase of a new product (tr = 4.3 min). The new 
product was collected and observed by ESI+-MS to produce an ion with m/z of 136.0607. 
This suggests the formation of an [M+H]+ ion of adenine with a theoretical mass of 
136.0618 within a mass deviation of 8 ppm. Adenine likely results as a consequence of 
SibS-catalyzed deglycosylation of SAM. The ESI+-MS of SAM itself also produces the 
same ion but this is accompanied by formation of other ions [methylthioadenosine+H]+and 
[adenosine-H2O+H]+ all of which result via fragmentation. SibS activity is an example of 
depurinase activity observed almost exclusively in DNA repair with nucleotide substrates. 
No SAM-dependent enzymes have been reported to promote the same reaction. There is 
no obvious explanation of how depurination is a productive step in PBD biosynthesis 
suggesting it is a non-native function. This promiscuous activity may stem from the shared 
active site features of SibS with superfamily members such as Aes1. Depurination is a 
reasonable biochemical function of Aes1, a protein known to enhance antisense-RNA 
mediated gene silencing.75 
Attempt to express and isolate SibT. SibS and SibZ either individually or together  
were unable to process a number of dihydropyrrole biosynthetic intermediates. If a 
multienzyme complex is necessary for SibS and SibZ to catalyze their respective reactions, 
SibT and SibY may be involved. These two proteins are the only predicted dihydropyrrole 


































Figure 3-7. HPLC chromatogram monitoring SibS-catalyzed depurination of SAM (tr = 



























































Figure 3-8. ESI+-MS of the products formed after incubation of SAM reacted with SibS 




available for forming a protein complex. SibT is expected to reduce 1.3 using a F420-Glu0 
cofactor derivative generated by SibY. To test if the absence of SibT impairs SibS and 
SibZ activity, the gene coding for SibT was cloned into a pSMT3 vector. BL21(DE3) E. 
coli, transformed with the vector, expressed SibT but in an insoluble form. The absence of 
its native cofactor may cause protein insolubility. Future attempts should include 
coexpression of SibT and SibY to see if this resolves the solubility issue.  
3.3 Summary 
 SibS, TomK and SibZ were produced as soluble proteins. However, SibS and 
TomK incubated with 1.1 did not generate the expected hydrolyzed products 1.2 and 
oxalate in the absence or presence of a divalent metal ion. Hydrolysis of 1.1 was expected 
to proceed via tautomerization of 1.1 but neither SibS nor TomK promote tautomerization 
of 1.1. SibS has affinity for 1.1 suggesting that either this ligand structurally resembles the 
substrate or is the substrate but requires an unidentified cofactor or protein for turnover. 
Surprisingly SibS did catalyze the depurination of SAM, likely a non-native reaction. The 
set of residues that coordinate 1.1 in the SibS crystal structure differs from the active site 
residues in functionally characterized DAP epimerase superfamily members suggesting 
SibS belongs to a new class of proteins within this superfamily.  
SibZ was produced as a soluble protein and incubated with the chemically 
synthesized 1.2. However, SibZ did not catalyze the methylation of 1.2 or its precursors L-
tyrosine, L-DOPA, L-2,3-secodopa and 1.1. Addition of Mg2+ or SibS did not activate SibZ-
catalyzed methylation. To assess if SibS and SibZ form a functional complex with SibT, 




3.4 Experimental Procedures 
 Materials. Oligonucleotides were obtained from Integrated DNA Technologies 
(Coralville, IA). PfuTurbo® DNA polymerase and its buffer were obtained from Stratagene 
(La Jolla, CA). Molecular biology grade DMSO was obtained from Sigma (St. Louis, MO). 
The QIAquick gel extraction kit was obtained from Qiagen (Valencia, CA). The GeneJet 
plasmid miniprep kit, dNTPs, T4 DNA ligase and its buffer were obtained from Fermentas 
(Glen Burnie, MD). SAM, restriction enzymes and their buffers were obtained from New 
England Biolabs (Ipswich, MA). The electrocompetent Rosetta2 strain was obtained from 
Novagen (Darmstadt, Germany). Oxalic acid dihydrate, barley seedling oxalate oxidase 
(0.71 U/mg), 3-methyl-2-benzothiazoline hydrazine hydrochloride monohydrate, N,N-
dimethylaniline (99%), horseradish peroxidase P-8375 (250-330 U/mg), ethylenediamine 
tetraacetic acid tetrasodium salt dehydrate and sodium citrate hydrate were all obtained 
from Sigma. All other relevant materials are described in Chapter 2. 
General methods. PCR was performed using an Eppendorf Mastercycler gradient 
(Hauppauge, NY). All plasmid constructs were confirmed by sequencing (UMBI or 
Genewiz). E. coli cells were lysed using an EmulsiFlex C3 homogenizer from Avestin 
(Ottawa, Canada). All other relevant general protocols are described in Chapter 2. 
Detection of oxalate using a coupled enzyme assay was performed according to the 
manufacturer’s (Sigma) instructions. HPLC analysis employed an Agilent 1000 series 
pump coupled to an 1100 wavelength detector and Phenomex 250 x 4.6 mm Jupiter C18 
analytical column with 5 µM particle size and 300 Å pore size (Torrance, CA). 
Fluorescence binding assays were conducted using a Hitachi F-4500 FL spectrophotometer 
generously provided by Dr. L. Isaacs at University of Maryland at College Park (UMCP) 
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(College Park, MD). The emission mode was selected in the FL solutions software and 
each scan was set to 2,400 nm/min with a 5 nm emission and excitation slot, 0.5 sec 
response time and 2 sec spin. THF and Et2O were dried over molecular sieves. 
Cloning of the sibZ and sibT genes. The genes encoding SibZ and SibT were 
amplified from the pSuperSib231 cosmid using alternatively a forward primer of 5’-
CCTTCTTGGATCCCGGGAATGGCAGGAC-3’ and a reverse primer of 5’-
CCTTCTTAAGCTTTCAATGGCGCTGGGTG-3’ or a forward primer of 5’-
AATTAATGGATCCCGGCACGGAGTCCTGATC-3’ and a reverse primer of 5’-
AATTATTAAGCTTTCATCCATCCCCCTGTAGGTG-3’. The PCR products were gel 
purified and digested with BamHI-HF and HindIII restriction enzymes. Each digested 
product was ligated with the linearized pSMT3 plasmid to generate pSMT3/sibZ or 
pSMT3/sibT alternatively. 
Expression of proteins. Expression was carried out under similar conditions 
described in Chapter 2 except for the following changes. Starter cultures consisted of either 
BL21(DE3) transformed with pSMT3/sibS,66 pSMT3/tomK67 or pSMT3/sibZ or Rosetta2 
transformed with pSMT3/sibT. An additional antibiotic, chloramphenicol (34 µg/mL), was 
added to Rosetta2 (DE3) cultures. The cell culture transformed with pSMT3/sibS was 
induced with D-lactose (0.2%) at 22 °C with agitation (12 h) while the cell culture 
transformed with pSMT3/sibT was induced with IPTG (50 µM) at 16 °C with agitation (15 
h). The cell culture transformed with pSMT3/sibZ was induced under identical conditions 
as the one transformed with pSMT3/sibV (Chapter 2). 
Purification of proteins. Purification of SibS, TomK and SibZ were carried out 
under similar conditions used for the purification of SibV described in Chapter 2 except 
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for the following changes. All purification steps were performed at 4 °C except for the 
chromatographic steps which were performed at room temperature while the buffers were 
kept on ice. TCEP (1 mM) was added to all the purification buffers instead of DTT. 10% 
glycerol was also included and the protease inhibitor benzamidine was excluded from all 
the purification buffers. Cells were lysed by four passages through an EmulsiFlex 
homogenizer at 15,000 psi. Proteins were concentrated in an Amicon ultra centrifugal filter 
(10,000 NMWL) (EMD Millipore) at 5,000 rpm. The resulting hydrolases were ≥ 95% 
pure as estimated by visual inspection after their separation by denaturing gel 
electrophoresis and staining with Coomassie Brilliant Blue. Enzyme solutions in gel 
filtration buffer were flash frozen in droplets with N2 (l) and stored at -80 °C until needed. 
Solubility assessment of His6-SUMO-SibT. Cells expressing His6-SUMO-SibT 
were lysed under identical conditions described above within the protein purification 
protocol. Protein solubility was analyzed after separation of the cell free extract by 
denaturing gel electrophoresis and staining with Coomassie Brilliant Blue. 
Determination of the oligomeric state of SibS. Size exclusion chromatography to 
measure the oligomeric state of SibS in solution was carried out under identical conditions 
described in Chapter 2. 
Mass spectrometry of SibS. Purified SibS was dialyzed (2 x 1 L) (12-14 kDa 
MWCO) against H2O for 4 h. The resulting desalted SibS was injected into a 100 mm x 
2.1 mm Poroshell C3 column (14%-51% CH3CN gradient in 0.1% aqueous formic acid 
over 15 min, 150 µL/min). Intact protein mass measurement was obtained in a full scan 
MS mode using an LTP Orbitrap XL mass spectrometer with 60,000 resolution and m/z 
400 in profile mode. 
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HPLC assay to detect hydrolase activity. SibS or TomK (1 µM) at 25 °C was 
incubated with 1.1 (1.0 mM) in sodium phosphate (25 mM pH 8.0) along with TCEP (1.0 
mM). Either MgCl2, ZnCl2 or MnCl2 (1.0 mM) was included in reaction mixtures testing 
for metal-dependence. Aliquots of the reaction mixture were quenched by addition of an 
equivalent volume of the HPLC elution buffer (aqueous 0.1% (v/v) formic acid pH 2.5) at 
various times (0, 2, 4, 6, 8, 10 and 24 h). Each sample was analyzed by HPLC as described 
in the general methods (30 min method, 1 mL/min). A negative control reaction was 
conducted excluding the protein. 
1H NMR assay to detect SibS and TomK activity. SibS and TomK (10 µM) were 
alternatively incubated at 25 °C with 1.1 (13 mM) in sodium phosphate (20 mM pH 8.0). 
The reaction mixtures were spiked with 10% D2O and monitored by 1H NMR spectroscopy 
for as long as 24 h. Negative control reactions were conducted by excluding either protein 
or substrate. 
Affinity of 1.1 for SibS. SibS (3 µM) was titrated with 1.1 over a range of 
concentrations (9-717 µM) in sodium phosphate (20 mM pH 8.0) at 25 °C. The 
fluorescence emission intensity (λem of 340 nm and λex of 290 nm) after each addition of 
ligand was recorded after the system reached equilibrium. An equivalent reaction where 
water was titrated as the ligand instead of 1.1 was used to account for changes in the 
fluorescence signals caused by dilution. An equation (Equation 3-1) that relates 
fluorescence emission intensity (F) to the endstate fluorescence emission intensities 
without ligand (F0) and with saturating level of ligand (Fb), total ligand concentration 
([L]T), total protein concentration ([P]T) and the equilibrium dissociation constant (KD) 
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describes the simple binding process and was used to fit for KD.71 Ῡ, calculated using 
(Equation 3-2), was plotted against [L]T on a logarithmic scale (Figure 3-2). 











Equation 3-2.                                       = 

 
Synthesis of 4-vinyl-4,5-dehydro-L-proline 1.2. 
 
N-Boc-4-triflate-4,5-dehydro-L-proline methyl ester 3.2 and N-Boc-4-triflate-
3,4-dehydro-L-proline methyl ester 3.2’ (Scheme 3-6). Synthesis of the enol triflate was 
based on protocols reported previously.77,80 A cold (-78 °C) solution of N-Boc-4-oxo-L-
proline methyl ester 3.1 (204 mg, 0.84 mmol) dissolved in THF (5 mL) was added to a cold 
(-78 °C) solution of anhydrous LiHMDS (1 M in THF, 1.26 mL, 1.26 mmol) diluted in 
THF (5 mL). The reaction mixture was purged with N2 (g) and stirred for 40 min at -78 °C. 
A cold (-78 °C) solution of PhN(OTf)2 (370 mg, 0.84 mmol) dissolved in DMPU (302 µL, 
2.5 mmol) and THF (5 mL) was injected into the reaction mixture and was stirred for 16 h 
during which the reaction temperature gradually increased from -78 °C to room 
temperature. The solvent in the reaction mixture was evaporated under reduced pressure 
and the remaining residue was dissolved in EtOAc (10 mL). The organic solution was 
washed with saturated NaHCO3 (10 mL), H2O (10 mL) and brine (10 mL). The aqueous 
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fractions were combined and back extracted with EtOAc (5 mL). The organic fractions 
were combined, dried under MgSO4 and evaporated under reduced pressure to yield a 
yellow residue. The residue was purified by silica gel column chromatography using 7.5% 
EtOAC and 7.5% CH2Cl2 in hexanes. The fractions containing desired material were 
evaporated under reduced pressure to yield a pale yellow oil (135 mg, 43% yield). Rf 0.3 
(7.5% EtOAC and 7.5% CH2Cl2 in hexanes). 1H NMR (400 MHz, CDCl3) δ 5.75 and 5.71 
(s(2), 1H), 5.08 and 5.01 (t(2), 1H), 4.47-4.22 (m, J=14, 6.3, 2H),  3.80 and 3.78 (s(2), 3H), 
1.49 and 1.44 (s(2), 9H). 13C NMR (CDCl3) δ 169.6 and 169.3, 146.3 and 145.8, 111.3 and 
111.1, 81.5 and 81.4, 63.7 and 63.1, 52.8 and 52.6, 50.3 and 50.0, 28.3 and 28.2. HRMS 
(FAB): m/z 376.0676 (M+H)+. Calcd for C12H16F3NO7S (M+H)+: 376.0672. 
N-Boc-4-vinyl-4,5-dehydro-L-proline methyl ester 3.3 and N-Boc-4-vinyl-3,4-
dehydro-L-proline methyl ester 3.-3’ (Scheme 3-6). Synthesis of the vinyl compound, 
specifically the coupling conditions used, was based on a protocol reported previously.76 
Pd(dba)2 (4 mg, 7 µmol), tri-(2-furyl)phosphine (3.4 mg, 15 µmol), ZnCl2 (34 mg, 0.25 
mmol) and Et2O (245 µL) was added to a solution of N-Boc-4-triflate-dehydro-L-proline 
methyl esters 3.2 and 3.2’ (49 mg, 0.13 mmol) dissolved in anhydrous NMP (6 mL). The 
reaction mixture was purged with N2 (g) and stirred for 10 min at room temperature. 
Bu3Sn(vinyl) (40 µL, 0.14 mmol) was injected into the reaction mixture and stirred for 18 
h at 60 °C under reflux. The reaction mixture was diluted in EtOAc (45 mL) and washed 
with H2O (2 x 45 mL) and brine (60 mL). The aqueous fractions were combined and back 
extracted with EtOAc (4 x 5 mL). The organic fractions were combined, dried under 
MgSO4 and evaporated under reduced pressure to yield a yellow oil. The oil was dissolved 
in CH3CN (20 mL) and washed with petroleum ether 40-60 (2 x 20 mL). The petroleum 
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ether was back extracted with CH3CN (3 mL). The CH3CN fractions were combined and 
evaporated under reduced pressured to a dark yellow oil. The oil was purified by silica gel 
column chromatography using 7.5% EtOAC and 7.5% CH2Cl2 in hexanes. The solvent in 
the desired material was evaporated under reduced pressure to yield a clear oil (20 mg, 
22% yield). Rf 0.2 (7.5% EtOAC and 7.5% CH2Cl2 in hexanes). 1H NMR (400 MHz, 
CDCl3) δ 6.50 and 6.38 (m, 1H), 5.68 and 5.63 (s(2), 1H), 5.32-4.98 (m, 2H), 5.09 and 5.01 
(s(2), 1H), 4.45-4.24 (m, 2H), 3.74 (s(2), 3H), 1.51 and 1.44 (s(2), 9H). 13C NMR (CDCl3) 
δ 171.0, 140.9, 130.0 and 129.8, 122.1 and 121.8, 118.2 and 117.7, 80.3, 66.8 and 66.4, 
52.3 and 52.2, 52.2 and 52.0, 28.4 and 28.3. HRMS (FAB): m/z 254.1389 (M+H)+. Calcd 
for C13H20NO4 (M+H)+: 254.1387. 
N-Boc-4-vinyl-4,5-dehydro-L-proline 3.4 and N-Boc-4-vinyl-3,4-dehydro-L-
proline 3.4’ (Scheme 3-6). N-Boc-4-vinyl-L-proline methyl esters 3.3 and 3.3’ (14 mg, 
0.05 mmol) were dissolved in THF (4.8 mL) and treated with LiOH (1 M in H2O, 1.6 mL). 
The reaction mixture was stirred for 24 h at room temperature. THF was evaporated under 
reduced pressure and the resulting white solid and aqueous solution was acidified with 
glacial acetic acid (58 µL, 1.00 mmol). The mixture above was diluted with CH3CN (0.1 
mL) and subjected to solid-phase extraction using a Sep-Pak that was preconditioned by 
washing with acetonitrile (9 mL) and H2O (9 mL) successively. Bound material was eluted 
with 5% CH3CN in H2O (6 mL) and 75% CH3CN in H2O (18 mL). The desired material 
was lyophilized to yield a clear oil (13 mg, 99% yield). 1H NMR (400 MHz, MeOD) δ 
6.55-6.44 (m, 1H), 5.83-5.75 (m, 1H), 5.23-5.08 (m, 2H), 4.86 and 4.83 (s(2), 1H), 4.44-
4.19 (m, 2H), 1.49 and 1.46 (s(2), 9H). 13C NMR (MeOD) δ 177.3 and 177.2, 139.4, 131.9, 
127.1 and 127.0, 116.6, 81.1, 71.4, 53.0, 28.9 and 28.7. HRMS (ESI+): m/z 262.1055 
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(M+Na)+. Calcd for C12H18NO4 (M+Na)+: 262.1050. λmax = 243 nm (diode array detector, 
64% CH3CN). 
4-Vinyl-4,5-dehydro-L-proline 1.2. N-Boc-4-vinyl-dehydro-L-prolines 3.4 and 
3.4’ (13 mg, 0.05 mmol) were dissolved in CH2Cl2 (0.1 mL) and treated with neat TFA 
(0.1 mL). The reaction mixture was stirred for 30 min in darkness at room temperature 
before it was placed under N2 (g) for 2 h to yield a yellow oil. The oil was dissolved in 
MeOH (4 mL) and washed with hexanes (3 x 2 mL). MeOH was removed by evaporation 
under reduced pressure to yield a yellow oil (7 mg, 99% yield). 1H NMR (400 MHz, 
MeOD) δ 6.59 (dd, J=18, 11, 1H), 5.97 (s, 1H), 5.39 (d, J=11, 1H), 5.31 (d, J=18, 1H), 
5.12 (s, 1H), 4.29 (dd, J=15, 2H). 13C NMR (MeOD) δ 139.3, 130.1, 123.1, 120.3, 68.4, 
52.1. HRMS (ESI+): m/z 140.0711 (M+H)+. Calcd for C7H10NO2 (M+H)+: 140.0706. λmax 
= 243 nm (diode array detector, 8% MeOH). 
SAM-dependent methyltransferase activity. SibZ (1 µM) was incubated at 25 °C 
with the putative substrate (86 µM) and the cosubstrate SAM (166 µM) in sodium 
phosphate (20 mM pH 8.0) along with TCEP (1.0 mM). MgCl2 (1.0 mM) was included 
when assaying for metal-dependence. An aliquot of the reaction mixture was quenched by 
addition of TFA (10% v/v) at various times (0, 0.5, 4 and 24 h). 12 µL of the quenched 
solution was mixed with an equivalent volume of the HPLC elution buffer (9% aqueous 
MeOH and 0.01% (v/v) TFA pH 2.2) and analyzed by HPLC as described in the general 
methods (30 min method, 0.5 mL/min, 254 nm detection). Positive control reactions were 




HPLC assay to detect depurinase activity of SibS. SibS (2.9 µM) was incubated 
at 25 °C with SAM (1.0 mM) in sodium phosphate (25 mM pH 8.0) along with TCEP (1.0 
mM). An aliquot of the reaction mixture was quenched by addition of an equivalent volume 
of the HPLC elution buffer (aqueous 0.1% (v/v) formic acid pH 2.5) at various times (0, 2, 
4 and 24 h). Each sample was analyzed by HPLC as described in the general methods (30 
min method, 0.5 mL/min, 254 nm detection). A negative control reaction was conducted 



















Understanding PBD biosynthesis involves studying not only the formation of the 
dihydropyrrole moiety but also its incorporation into the natural product. The PBD gene 
cluster contains a pair of biosynthetic genes predicted31 to code for non-ribosomal peptide 
synthetases (NRPSs), a class of enzymes known to assemble moieties into natural products. 
NRPSs are large enzymes equipped with an assembly line of domains that link amino acid 
or carboxylic acid substrates into complex natural products. Before discussing specifically 
how the predicted NRPSs can assemble a PBD, it is necessary to understand the typical 
NRPS enzymatic steps (Scheme 4-1). It involves an assembly process that initiates with 
an Mg2+-dependent adenylation domain selecting and activating an acid substrate using 
ATP. Adenylation forms an acyl adenylate, the substrate for a thiolation domain. The 
thiolation domain forms a thioester bond between its post-translationally loaded 
phosphopantetheine arm on a conserved serine and the acyl adenylate. A condensation 
domain forms a peptide bond between two thioester compounds each conjugated to a 
thiolation domain. The resulting peptide remains covalently tethered onto a single 
thiolation domain. The adenylation, thiolation and condensation steps repeat to grow the 
peptide chain until either a thioesterase or reductase domain terminates the assembly 
process by cleaving the peptide from the thiolation domain. 
Sibiromycin is proposed to assemble in accordance with the NRPS paradigm 





Scheme 4-1. NRPS-mediated reactions with two amino acid substrates via their activation, 
thiolation and condensation to yield a dipeptide that is then reductively cleaved from the 
NRPS. 
 
and thiolation domain. In vitro adenylation and thiolation assays showed that SibE 
adenylates an anthranilate compound derived from L-tryptophan and attaches the activated 
anthranilate onto its thiolation domain in preparation for its assembly into sibiromycin.24 
SibD and its homologs associated with related natural products each contain a 
condensation, adenylation, thiolation and reductase domain based on the presence of their 
respective signature motifs.81 The following steps were proposed31 taking into account the 
available domains and the structure of sibiromycin. SibD adenylates the dihydropyrrole 
moiety derived from L-tyrosine and the resulting activated dihydropyrrole forms a thioester 
linkage with the thiolation domain. The condensation domain uncouples the anthranilate 
compound from SibE and couples it to the dihydropyrrole moiety via a peptide bond. The 
reductase domain releases the dipeptide from SibD via a two-electron reduction using 
NADPH consistent with a Rossman fold present in the reductase, a signature nucleotide 





Scheme 4-2. SibE and SibD are proposed to activate, thiolate and condense the anthranilate 
and dihydropyrrole moieties derived from L-tryptophan and L-tyrosine, respectively. SibD 
likely reductively releases the dipeptide that undergoes a ring closure. Putative 
glycosyltransferase SibH catalyzes the transfer of the sibirosamine sugar onto the tricyclic 
aglycone to yield sibiromycin. 
 
in the dihydropyrrole ring to form the diazepine ring. Putative glycosyltransferase SibH 
adds a sibirosamine sugar onto the tricyclic sibiromycin aglycone furnishing the PBD. The 
last two steps were proposed to occur post NRPS assembly of the dipeptide although the 
order and timing of these steps are speculative. 
The typical NRPS steps are sometimes interrupted by additional modifications to 
the compound while it is loaded on the thiolation domain. For instance, SibG catalyzes the 
FAD/NADH-dependent hydroxylation of an anthranilate moiety precursor, 3-hydroxy-4-
methylanthranilic acid, only once it is covalently attached to SibE (3-hydroxy-4-
methylanthranilic acyl-S-SibE) (Scheme 4-3).24,82 In analogy, SibD may activate and 
thiolate the final dihydropyrrole moiety or one of its precursors. The latter scenario would 
warrant a revision to the proposed dihydropyrrole biosynthetic pathway (Scheme 1.6) as 




Scheme 4-3. SibG-catalyzed hydroxylation of 3-hydroxy-4-methylanthranilic acyl-S-
SibE. 
 
Deletion of orf22 and npsB, the sibD orthologs in the anthramycin and tilivalline 
producers, respectively, led to mutant strains that did not produce the expected PBD,23,34 
suggesting in analogy that SibD is also essential in sibiromycin biosynthesis. We chose to 
monitor SibD’s adenylation and thiolation reactions in vitro to gain insight into the timing 
of these NRPS reactions relative to the dihydropyrrole modification steps. Answering this 
question involved production of an adenylation and thiolation didomain from SibD and 
testing each domain for activity using a panel of dihydropyrrole pathway intermediates as 
substrates.  
4.2 Results and Discussion 
Production of the adenylation and thiolation didomain in SibD. Amplification 
of the sibD gene (4512 bp) from cosmid DNA produced only truncated PCR products even 
under a condition that amplified a similarly sized (3252 bp) NRPS-encoded gene.83 
Although a synthetic gene could have been used in place of the PCR product, efforts to 
pursue heterologous expression of SibD were abandoned as solubility issues were 
anticipated due to the large size (1503 amino acids) of the protein. Expression of specific 
domains within the NRPS is a common strategy to overcome the lack of solubility of intact 
NRPSs. This requires identification of domain boundaries.  
Many programs predict domain boundaries but require structural information of 
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related proteins.84 No structures for multidomain intact NRPSs similar to SibD appear in 
the PDB85 limiting the choice of methods to ab initio methods. Among these, the Udwary-
Merski algorithm86 (UMA) was a promising program as it extracts information from 
homologous sequences, available for SibD (TomB, Orf22, Por21, NpsB). Although 
initially developed to predict domain boundaries of polyketide synthases, another class of 
multidomain enzymes that assemble natural products, UMA has successfully predicted 
domain boundaries in NRPSs.87 UMA defines boundaries by analyzing homologous 
sequences, primary sequence neighboring hydrophobicity and secondary structure of 
multidomain proteins. Low UMA scores for certain amino acids (504E, 1024R, 1123R, 
1182A) in SibD predict they belong to a linker region (Figure 4-1). The predicted domains 
encompassed by the linker regions were verified by the presence of signature motifs of 
each domain.81 This analysis indicated that 1182A does not belong to a linker region as it 
is between the R2 and R3 motifs in the reductase domain.  
PCR primers were designed to anneal the nucleotides that code for the linker 
regions in SibD prior to the adenylation domain and past the thiolation domain. A truncated 
PCR product formed instead of the desired gene fragment coding for the adenylation and 
thiolation domains in SibD (sibDAT). Two sets of PCR primers were used instead to amplify 
the gene fragment as two overlapping pieces and were cloned sequentially into the pSMT3 
vector. This allowed for the production of SibDAT fused to an N-terminal His6-SUMO tag. 
The post-translation phosphopantetheinylation of the thiolation domain is 
necessary to render SibDAT fully functional. The sibiromycin gene cluster lacks a gene that 
codes for an enzyme that installs the phosphopantetheine arm on the thiolation domain. An 







Figure 4-1. UMA prediction graph for SibD domain boundaries illustrated at low UMA 
scores. The thiolation domain is commonly referred to as the acyl carrier protein (ACP). 
 
BAP-1,88 was selected to express SibDAT and load the phosphopantetheine arm on the 
thiolation domain. Upon expression, the post-translational modification was assumed to 
have occurred at the only conserved serine (S1067 in SibD) in the thiolation domains of 
SibD and related NRPSs. SibDAT was purified via Ni-NTA affinity chromatography, 
subjected to Ulp1-catalyzed removal of the SUMO fusion and further purified via size 
exclusion chromatography. Purification yielded ca. 8 mg protein per liter of growth media 
(Appendix C-1). SibDAT was denatured, digested with trypsin and subjected to tandem 
MS analysis. Identification of the predicted peptides verified the presence of the desired 
post-translational modification at S1067 (Appendix C-2). The peptide of interest 
possessing the phoshopantetheine arm had a parent ion experimental mass of 3477.7141 
Da in agreement with its theoretical mass of 3477.6296 Da within a mass deviation of 24 
ppm. Identification of this peptide was further confirmed by detection of several of its 
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terminus (b ions) or carboxyl terminus (y ions) of the peptide (Appendix C-3 and C-4). 
For example the y23 ion containing the phosphopantetheinylated serine (y23*) had an 
experimental mass of 2584.1799 Da in agreement with its theoretical mass of 2584.1050 
Da within a mass deviation of 29 ppm. The parent ion corresponding to the apo version of 
the peptide lacking the phosphopantetheine arm was not observed. These results indicate 
the successful expression and purification of the phosphopantetheinylated SibDAT 
didomain. 
Adenylation by SibDAT. With holo-SibDAT in hand, the next step was to determine 
the viability and substrates of the adenylation and thiolation domains. Since the final 
dihydropyrrole compound (2S,4R)-4-(Z)-propenylproline is incorporated into the 
structurally related natural product hormaomycin by action of its appropriate adenylase in 
the NRPS HrmP,89  the final dihydropyrrole compound in sibiromycin, L-4-propenyl-4,5-
dehydroproline 1.5, is proposed to be the substrate for SibDAT (Scheme 4-4). This 
compound was synthesized under identical conditions that generated L-4-vinyl-4,5-
dehydroproline 1.2 (Chapter 3) except propenyltributyltin was used as the coupling 
reagent. Although this substitution from its vinyl counterpart was tolerated by Stille 
coupling, the yield dropped to 11%. It is unknown if less starting material reacted, more 
side products formed or more product decomposed although the same number of 
compounds were present in the vinylation reaction as judged by UV irradiation and 
ninhydrin treatment of thin layer chromatography (TLC) plates spotted with the crude 
reaction. 
A radioactivity based activity assay routinely used to detect the reversible exchange 




Scheme 4-4. Adenylation reactions known or proposed to initiate incorporation of the 
pyrrolidine or dihydropyrrole moiety in hormaomycin and sibiromycin, respectively. 
 
formation of the amino acyl-adenylate (Scheme 4-5). A reaction mixture consisting of 
SibDAT (0.25 µM), putative substrate L-4-propenyl-4,5-dehydroproline 1.5 (0.8 mM), 
cosubstrate ATP (3.7 mM) and Mg2+ (7.5 mM) in the presence of PPi (1.0 mM) and 
[32P]PPi (1 µCi) did not generate [32P]ATP above background counts (Figure 4-2). The 
conditions were similar to those used previously24 to detect adenylation by SibE suggesting 
either the substrate was incorrect or SibDAT was inactive. 
One of the precursors of L-4-propenyl-4,5-dehydroproline 1.5 may instead be the 
adenylase substrate. Lincomycin A established a precedent for a precursor ((2S,4R)-4-
propyl-L-proline) to be incorporated into the natural product90 prior to an N-methylation 
step that furnishes its final pyrrolidine moiety (Scheme 4-6).91 Among the proposed 
sibiromycin dihydropyrrole intermediates in the pathway, the commercially available ones 
(L-tyrosine and L-DOPA), enzymatically accessible one (L-4-(2-oxobutenoate)-4,5- 




Scheme 4-5. Radioactive adenylation assay that monitors amino acyl-adenylate formation 
indirectly though the reversible exchange of [32P]PPi with ATP followed by the capture of 
the resulting [32P]ATP onto charcoal. 
 
were tested as substrates. Only L-tyrosine was adenylated by SibDAT generating [32P]ATP 
above background counts (Figure 4-2A). Often an adenylase can activate some common 
amino acids in addition to its native substrate. For example the SibD homolog HrmP 
activates L-threonine at 10% of the efficiency of its native substrate.90 L-threonine, an 
amino acid with no obvious place in the pathway for sibiromycin was tested as a substrate. 
Using L-threonine, equivalent counts of [32P]ATP formed within error (680 ± 253 cpm) 
compared with L-tyrosine (589 ± 224 cpm). This suggests that L-tyrosine may also be a 
non-native substrate. For comparison, much higher counts (30962 ± 9064 cpm) are 
observed when monitoring the adenylation of L-serine, the native substrate for another 
NRPS NocB(A4T4) and its partner protein NocI (Figure 4-2B).99 
 
Scheme 4-6. Adenylation of a pyrrolidine precursor before assembly into lincomycin A. 
 
Two intermediates expected to form prior and subsequent to the SibT-catalyzed 
reduction remain untested as adenylation substrates (Scheme 4-7). The former, 1.3, 
consists of a 1-pyrroline ring while the latter consists of a proline ring 1.4. The closest 
commercially available analogs of 1.4 (L-proline, L-trans-4-methylproline, L-cis-4-
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hydroxyproline and L-3,4-dehydroproline) (Scheme 4-8) were also tested but none 
generated [32P]ATP above background in this partial reaction. This is surprising given that  
 
Figure 4-2. Probing for substrate activation by the adenylation domain in SibDAT via 
monitoring [32P]ATP formation as a consequence of ATP/[32P]PPi exchange during 
adenylation. Each measurement represents the average of three independent trials. The 
error bars represent one standard deviation of uncertainty. A) Adenylation by SibDAT is 
shown. B) The adenylation of L-serine by another NRPS NocB(A4T4) and its partner 
protein NocI is shown in red for comparison. 
 
 
Scheme 4-7. The substrate and product in the proposed SibT-catalyzed reduction step are 
possible substrates for the adenylation domain in SibDAT. 
adenylases often activate substrate analogs, albeit less efficiently. For example, HrmP 















































might be explained by a highly specific adenylation domain but this is contradicted by the 
ability of SibDAT to activate at least two common amino acids as substrates. 
 
Scheme 4-8. Available analogs for the proposed SibT product 1.4 that were tested as 
substrates for the adenylation domain in SibDAT. 
The adenylation domain in SibDAT is active but the absence of the condensation 
(SibDC) and reductase (SibDR) domains resulting in missing interdomain interactions may 
attenuate activity with the native substrate below levels of detection. To confirm that 
SibD’s other domains are not necessary to detect adenylation of the native substrate, new 
plasmid constructs were cloned for expression and purification of the two missing domains 
as separate polypeptides. The two gene fragments sibDC and sibDR coding for SibDC and 
SibDR, respectively, were predicted with aid of UMA (Figure 4-1). The gene fragment 
sibDC was synthesized (GenScript) as PCR amplification failed. Both gene fragments were 
cloned into a single pACYCDuet-1 plasmid utilizing both multiple cloning sites. The 
vectors pACYCDuet-1/sibDC/sibDR and pSMT3/sibDAT containing compatible replicons 
and independent antibiotic selections were sequentially transformed and co-expressed in 
BAP-1 E. coli cells. The expressed proteins were simultaneously purified via Ni-NTA 
affinity chromatography, Ulp1-catalyzed proteolysis and size exclusion chromatography 
and yielded ca. 2 mg pure proteins per liter of growth media. An aliquot containing the 
purified proteins was denatured, digested with trypsin and subjected to tandem MS 
analysis. Detection of multiple peptides belonging to SibDC and SibDAT confirmed their 
successful co-purification. No peptides belonging to SibDR were detected. Unlike SibDC 
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and SibDAT, SibDR was expressed without the N-terminal His6-SUMO-tag. The 
purification conditions appear to disrupt the interdomain interactions necessary for SibDR 
to co-purify with SibDC and SibDAT. Instead the sibDR gene fragment was subcloned for 
separate expression and purification as an N-terminal His6-SUMO fusion protein. 
Adenylation by SibDAT with or without purified SibDC and SibDR added in vitro 
was tested against all the previously tested substrate candidates. The presence of molar 
equivalents of SibDC and/or SibDR to SibDAT during adenylation of all substrates except 
L-tyrosine did not generate [32P]ATP counts above background counts. L-tyrosine 
adenylation by SibDAT with a molar equivalent of SibDC and/or SibDR generated 
equivalent [32P]ATP counts within error compared to SibDAT alone (Figure 4-3). This 
suggests that the addition of the condensation and reductase domains are no effective for 
optimal adenylation activity although the native confirmation of SibD may require 
production of it as a single polypeptide. 
Thiolation by SibDAT. The adenylation reaction is only the first step toward 
acylating SibD’s substrate. In the second step, the amino acyl adenylate is expected to form 
a thioester bond with the phosphopantetheine arm on the thiolation domain. The 
radioactivity assay monitors only the first of two partial reactions that constitute acylation. 
Adenylation alone may not reflect substrate selectivity of the acylation reaction. A mixture 
consisting of the reaction components necessary to form the L-tyrosinyl-adenylate was 
assayed to determine if it was subsequently covalently attached to SibDAT to form L-
tyrosinyl-S-SibDAT.  
SibDAT from the adenylation reaction mixture was denatured and digested with 




Figure 4-3. Effect of including the SibDC and/or SibDR domain during L-tyrosine 
adenylation by SibDAT assessed by the ATP/[32P]PPi exchange assay. Each measurement 
represents the average of three independent trials. The error bars represent one standard 
deviation of uncertainty. 
bearing peptides either conjugated to (Appendix C-5 and C-6A) or free of (Appendix C-
5 and C-7A) L-tyrosine were detected. The peptide of interest bearing the 
phosphopantetheine arm conjugated to L-tyrosine was detected with an experimental mass 
of 3639.7837 Da in agreement with its theoretical mass of 3639.8298 Da within a mass 
deviation of 13 ppm. Several daughter b and y ions that differentiate between the acylated 
and unacylated peptides further supported their identities. For example the detection of 
acylated fragment peptide ions (y17*, y23* and y24*) with a mass deviation of 29, 18 and 
15 ppm, respectively, indicated the formation of the acylated peptide (Appendix C-6B) 
while the detection of an unacylated fragment peptide ion (y28*) with a mass deviation of 
28 ppm indicated also the presence of the unacylated peptide (Appendix C-7B). The 
presence of both sets of peptides indicate a mixture of L-tyrosinyl-S-SibDAT and unacylated 
SibDAT species were formed during adenylation and thiolation. The identical experiment 























Replacing L-tyrosine with L-threonine, L-4-vinyl-4,5-dehydroproline 1.2 or L-4-propenyl-
4,5-dehydroproline 1.5 as the substrate only generated unacylated peptides (Appendix C-
8, C-9 and C-10). We conclude that SibDAT is capable of catalyzing both adenylation and 
thiolation of L-tyrosine. 
Dioxygenation of substrate analogs mimicking L-DOPA tethered onto SibD. If 
the native substrate for SibD is L-tyrosine, it follows that formation and modification of the 
dihydropyrrole moiety occurs after L-tyrosine is tethered to the thiolation domain. If this is 
the case, SibU should preferentially catalyze the hydroxylation of L-tyrosinyl-S-SibD over 
L-tyrosine. Similarly, SibV should preferentially catalyze the dioxygenation of L-DOPA-S-
SibD over L-DOPA. Heterologous expression of SibU produced only insoluble protein 
even when expressed as an His6-SUMO fusion protein93 preventing study of the former 
reaction so the latter reaction was investigated instead. L-DOPA-N-acetylcysteamine (L-
DOPA-SNAC) 4.1a and L-DOPA-pantetheine 4.1b were synthesized to serve as an analogs 
for L-DOPA-S-SibD and be tested as substrates for SibV (Scheme 4-8). The SNAC moiety 
resembles the extremity of the phosphopantetheine arm. Replacing the acylated NRPS with 









A published protocol96 was used to generate L-DOPA-SNAC 4.1a and also adapted 
to generate L-DOPA-pantetheine 4.1b. In both syntheses, L-DOPA was protected with an 
N-Boc group 4.3 (Appendix C-11) before converting it into a thioester 4.4 using PyBOP 
and benzenethiol. These steps proceeded under N2 (g) to prevent polymerization of L-
DOPA. This modification was not reported previously and appeared to increase the yield 
over the two steps from the reported96 6% to 63%. The desired thiophenolate ester 4.4 was 
confirmed by UPLC-ESI+-MS. An experimental parent ion mass corresponded to the 
deprotected compound 4.5 (m/z 290.0850 [M-Boc+H]+) expected under the acidic 
conditions used in the UPLC (Appendix C-12) and in agreement with the theoretical mass 
(m/z 290.0845 [M-Boc+H]+) within a mass deviation of 1.7 ppm. The mass of the most 
intense signal corresponds to a fragment ion (experimental m/z = 152.0722) that forms 
upon dehydration and decarbonylation of the L-DOPA fragment ion (theoretical m/z = 
152.0706) reported previously.97 The 1H and 13C NMR signals for N-Boc-L-DOPA-
thiophenol 4.4 (Appendix C-13) agreed with the reported96 literature values. 
Transthioesterification with the SNAC thiol proceeded after the Boc deprotection step. 
Similarly, transthioesterification with the pantetheine dimethyl ketal thiol proceeded prior 
to the Boc deprotection step to prevent premature acetal deprotection. TFA removed the 
acid-labile protecting groups to form L-DOPA-SNAC 4.1a and L-DOPA-pantetheine 4.1b. 
The products were partially purified by RP-HPLC as they co-eluted with their respective 
deprotected thiol starting material (SNAC or pantetheine). Using ammonium 
formate/formic acid instead of the reported ammonium acetate/acetic acid as an HPLC 
buffer removed an interfering signal during NMR analysis. Two sets of 1H NMR signals 
were observed in the spectrum of each partially purified product confirming a mixture of 
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the desired product 4.1a or 4.1b and the thiol (Appendix C-14 and C-15) at a 4:1 ratio. 
Assignment of the 1H signals was based on a model compound, L-tyrosine-SNAC as they 
were not reported for 4.1a.94 Product identities were further confirmed by UPLC-ESI+-MS 
that generated experimental parent ion masses (m/z 299.1068 and 458.1949 [M+H]+) in 
agreement with the theoretical masses (m/z 299.1060 and 458.1955 [M+H]+) within a mass 
deviation of 2.7 and 1.3 ppm corresponding to L-DOPA-SNAC 4.1a and L-DOPA-
pantetheine 4.1b, respectively (Appendix C-16 and C-17). 
L-DOPA-SNAC 4.1a and L-DOPA-pantetheine 4.1b were tested as alternative 
substrates of SibV to probe if dioxygenation of L-DOPA-S-SibD occurs. L-DOPA-SNAC 
4.1a treated with SibV generated an experimental mass ion (m/z = 312.9641 [M+]) in 
agreement with the theoretical mass (m/z = 313.0853 [M+]) of 1.1-SNAC 4.2a expected to 
form upon dioxygenation and ring closure (Figure 4-4). This mass signal was not observed 
if SibV or the substrate 4.1a were left out of the reaction mixtures, serving as negative 
controls. However L-DOPA dioxygenation required a lower amount of SibV (0.1 mol %) 
to detect an observable product 1.1 signal in the HPLC spectrum whereas L-DOPA-SNAC 
4.1a required more SibV (27 mol %) to detect an observable product 4.2a signal. SibV 
treatment of L-DOPA-pantetheine 4.1b generated mass ions corresponding to 
unidentifiable compounds. Neither the expected dioxygenation product 1.1-pantetheine 
4.2b nor its fragment generated via the equivalent fragmentation pattern (Appendix C-17) 
observed in 4.1b were detected. SibV appears to favor catalysis of free L-DOPA over its 
conjugated thioester counterparts. This suggests SibV favors dioxygenation of free L-
DOPA over L-DOPA-S-SibD although the latter may still prove to be the biosynthetically 
productive step.  
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One explanation for the absence of activity upon SibS or SibZ treatment of L-4-(2-
oxobutenoate)-4,5-dehydroproline 1.1 (Chapter 3) is that these reactions only proceed if  
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Figure 4-4. ESI+-MS of solvent with (top) or without (bottom) 1.1-SNAC 4.2a. Both y-
axes are the same scale with respect to the total ion count. The parent ion [M]+ is detected. 
 
their substrate is covalently attached to SibD. SibS and SibZ were incubated separately or 
as a putative protein complex with the 1.1-SNAC 4.2a generated in situ by SibV-catalyzed 
L-DOPA-SNAC 4.1a dioxygenation. These reactions were performed in the absence and 
presence of Mg2+ to see if it was necessary. The enzymatic mixtures were fractionated via 
ion-pair RP-HPLC (IPRP-HPLC). IPRP-HPLC prevented the substrate and potential 
products from co-eluting at the void volume with buffering reagents and metals unlike 
alternative used of C4, C8, C14-amide or C18 RP-HPLC. In each case, the HPLC spectrum 
signals appeared identical to the negative control in the absence of SibS, SibZ or both 
enzymes. No new signal corresponding to product formation was detected. It is important 
to note that SNAC compounds often fail to replace their NRPS counterparts as substrates96 
so such studies cannot conclusively rule out the possibility of SibS and SibZ catalyzing 















SibDAT, the truncated version of SibD containing the adenylation and thiolation 
didomain was produced as a soluble and active protein. The thiolation domain contained 
the post-translationally installed phosphopantetheine group on its serine residue necessary 
for thiolation activity. SibDAT was expected to adenylate the product 1.5 of dihydropyrrole 
moiety biosynthesis. SibDAT adenylated L-tyrosine instead, the metabolic precursor in the 
pathway. The added presence of SibD’s condensation and reductase domains did not affect 
adenylation activity as evident by a radioactive adenylation assay. Following adenylation, 
L-tyrosine was covalently conjugated to the thiolation domain as a thioester on the 
phosphopantetheine arm. 
L-tyrosine may be a non-native substrate. If L-tyrosine is SibD’s native substrate, 
L-DOPA-S-SibD should be an intermediate of the biosynthetic pathway. However, SibV 
prefers to catalyze the dioxygenation of L-DOPA over two L-DOPA-S-SibD analogs (L-
DOPA-SNAC 4.1a and L-DOPA-pantetheine 4.1b). SibDAT also adenylates L-threonine, 
suggesting adenylation of certain common amino acids represents ancestral traits of SibD 
and not native activity. Two putative biosynthetic intermediates 1.3 and 1.4 are not 
currently available and may instead be the native substrate although surprisingly SibDAT is 
incapable of adenylating structurally similar compounds. 
4.4 Experimental Procedures 
Materials. The pACYCDuet-1 plasmid was obtained from Novagen (Darmstadt, 
Germany). Phusion high-fidelity DNA polymerase and its HF buffer were obtained from 
Finnzyme (Fair Lawn, NJ). T4 DNA ligase and its buffer were obtained from Promega 
(Madison, WI). The BAP-188 strain of E. coli was generously donated by Dr. C. Khosla at 
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Stanford University (Stanford, CA). Sequencing grade trypsin was obtained from Promega 
(Madison, WI) and 10 µL reverse-phase ZipTipµ-C18 was obtained from EMD Millipore 
(Darmstadt, Germany). [32P]-Tetrasodium pyrophosphate was obtained from PerkinElmer 
(Waltham, MA). PyBOP was obtained from EMD Millipore. Pantetheine dimethyl ketal98 
and the expression vectors for NocB(A4T4) and NocI99 were generously donated by Dr. C. 
Townsend at Johns Hopkins University (Baltimore, MD). All other relevant materials are 
described in previous chapters. 
General methods. Codon optimization and DNA synthesis were performed by 
GenScript (Piscataway, NJ). Domain boundaries in SibD were predicted using the Udwary-
Merski (UMA) algorithm.86 NRPS protein domains were analyzed by SDS-PAGE made 
with 14% resolving and 4% stacking acrylamide layers. Peptide mass measurements were 
obtained in the ESI+ mode using the Waters Acquity UPLC-Xevo-G2-aTof-MS (Milford, 
MA) equipped with a 2.5 mm x 150 mm BEH-C4 column (1.7 µM and 300 Å pore size) 
using a 5-80% aqueous acetonitrile gradient in 0.1% formic acid over 60 min (0.3 mL/min). 
Sequences for peptides were identified using BioPharmaLynx 1.4.3 and with a mass 
tolerance of 0.25 Da, MS and MSE mass match tolerance of 30.0 ppm and trypsin digest 
with 0 missed cleavages. Scintillation counting was performed with a PerkinElmer TriCarb 
2910 TR liquid scintillation counter. NMR experiments were performed on a Bruker 300 
MHz for the L-DOPA thioesters. L-DOPA thioesters concentrations were estimated using 
the ε280 nm of L-DOPA (Chapter 2). HPLC analysis employed a Jasco PU-980 intelligent 
HPLC pump equipped with a HG-903-31 solvent mixing module, MD-1510 diode array 
(PDA) detection and Phenomex 250 x 4.6 mM Jupiter C18 analytical column with 5 µM 
particle size and 300 Å pore size (Torrance, CA). IPRP-HPLC was performed with 
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triethylamine (15 mM) and acetic acid (21 mM) (pH 5.0) as the aqueous mixture. 
Separation consisted of isocratic elution over 15 min, then a 5-95% methanol gradient over 
10 min, followed by a 95% methanol isocratic step over 10 min. All other relevant general 
protocols are described in previous chapters. 
Cloning of the sibDAT gene fragment. The gene fragment encoding SibDAT was 
cloned sequentially in two pieces using an internal restriction site. The sibDAT(1700-3366) gene 
fragment corresponding to nucleotides 1700-3366 in the sibD gene was amplified from the 
pSuperSib131 cosmid using a forward primer of 5’-
CCTTCTTGGATCCCCGGCGCGGCAGTC-3’ and a reverse primer of 5’-
CCTTCTTAAGCTTTCACGTGTCGGCCCACAGG-3’. The PCR product was gel 
purified and digested with BamHI-HF and HindIII restriction enzymes. The resulting 
fragment was ligated with the linearized pSMT3 plasmid to generate pSMT3/sibDAT(1700-
3366). The sibDA(1465-2100) gene fragment harboring the 5’ adenylase-encoding nucleotides 
1465-2100 in the sibD gene was amplified from the pSuperSib1 cosmid using a forward 
primer of 5’-CCTTCTTGGATCCCAGCGGGTGCACGACC-3’ and a reverse primer of 
5’-CCTTCTTGGTCTCGCCGAGTCCG-3’. The PCR product was gel purified and 
digested with BamHI-HF and BsaI restriction enzymes. The fragment was then ligated with 
the linearized pSMT3/sibDAT(1700-3366) vector to generate pSMT3/sibDAT. 
Cloning of the sibDC and sibDR gene fragments. The gene fragment encoding 
SibDC was synthesized with a 3’-opal stop codon and the remaining codons were optimized 
for expression in E. coli (Appendix C-18). This was cloned into the pUC57-Kan plasmid 
flanked by 5’-BamHI and 3’-HindIII restriction sites (pUC57/sibDC) (GenScript). The 
gene fragment encoding SibDR was amplified from the pSuperSib131 cosmid using a 
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forward primer of 5’-AATTAATGGATCCATGCGTCTGCTGGACGGGTTG-3’ and a 
reverse primer of 5’-AATTAATAAGCTTTCATGGCGCCGAGGTAGG-3’ and the PCR 
product was gel purified. The corresponding gene fragments were digested with BamHI-
HF and HindIII restriction enzymes and ligated with the linearized pSMT3 plasmid to 
generate pSMT3/sibDC and pSMT3/sibDR alternatively. 
Subcloning of the sibDC and sibDR gene fragments into a co-expression vector. 
The sibDC gene fragment from the pUC57/sibDC vector was subcloned into multiple 
cloning site #1 in the pACYCDuet-1 plasmid using the 5’-BamHI and 3’-HindIII 
restriction sites to generate pACYCDuet-1/sibDC(off-frame). The codons in sibDC were off-
frame from its upstream start codon, an unavoidable consequence of using the restriction 
sites available for subcloning. The sibDR gene fragment was amplified from the 
pSMT3/sibDR vector using a forward primer of 5’-
AATTAATCATATGCGTCTGCTGGACGGGTTG-3’ and a reverse primer of 5’-
AATTAATCAATTGTCATGGCGCCGAGGTAGG-3’. The PCR product was gel 
purified and digested with NdeI and MfeI restriction enzymes. It was ligated with the 
linearized pACYCDuet-1/sibDC(off-frame) vector into multiple cloning site #2 to generate 
pACYCDuet-1/sibDC(off-frame)/sibDR. To correct the reading frame of the sibDC codons, both 
the pACYCDuet-1/sibDC(off-frame)/sibDR and pSMT3/sibDC vectors were digested with 
NcoI, taking advantage of an internal restriction site within the sibDC gene fragment and 
then religated to generate pACYCDuet-1/sibDC/sibDR. 
Expression of proteins. Expression was carried out under similar conditions 
described in Chapter 2 except for the following changes. Starter cultures consisted of either 
BAP-1 transformed with pSMT3/sibDAT or sequentially transformed with pSMT3/sibDAT 
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and pACYCDuet-1/sibDC/sibDR or Rosetta2(DE3) transformed with pSMT3/sibDR. An 
additional antibiotic, chloramphenicol (17 µg/mL) was included in addition to kanamycin 
(25 µg/mL) in the BAP-1 cell culture containing two plasmids and the Rosetta2(DE3) cell 
culture. All cell cultures were ultimately induced at 16 °C with IPTG (20 µM). Expression 
of Noc(A4T4) and NocI is reported.99 
Purification of proteins. Purification was carried out under similar conditions for 
purification of SibV described in Chapter 2 except for the following changes. All 
purification steps were performed at 4 °C except for the chromatographic steps which were 
performed at room temperature while the buffers were kept on ice. Cells were lysed by four 
passages through an EmulsiFlex homogenizer at 15,000 psi. Proteins were concentrated in 
an Amicon ultra centrifugal filter (10,000 NMWL) (EMD Millipore) at 5,000 rpm. All 
proteins were ≥ 95% pure as estimated by visual inspection after their separation by 
denaturing gel electrophoresis and staining with Coomassie Brilliant Blue. Purification of 
Noc(A4T4) and NocI is reported.99 
Synthesis of L-4-propenyl-4,5-dehydroproline 1.5. Synthesis was carried out 
under identical conditions to those described in Chapter 3 except Bu3Sn(vinyl) was 
replaced with Bu3Sn(propenyl) (43 µL, 0.14 mmol). 
N-Boc-4-propenyl-4,5-dehydro-L-proline methyl ester 4.6 and N-Boc-4-
propenyl-3,4-dehydro-L-proline methyl ester 4.6’. 1H NMR (400 MHz, CDCl3) δ 6.12 
and 5.91 (m, 1H), 5.68 and 5.67 (s(2), 1H), 5.61-5.41 (m, 1H), 5.04 and 4.95 (s(2), 1H), 
4.55-4.16 (m, 2H), 3.72 (s(2), 3H), 1.79 (s(2), 3H), 1.48 and 1.42 (s(2), 9H). 13C NMR 
(CDCl3) δ 171.3, 153.4, 140.6 and 139.8, 130.4 and 129.7, 122.6 and 121.8, 119.0 and 
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118.7, 80.2, 66.7 and 66.0, 55.0 and 54.6, 52.5 and 52.2, 28.3. HRMS (ESI+): m/z 290.1364 
(M+Na)+. Calcd for C14H21NO4 (M+Na)+: 290.1363. 
N-Boc-4-propenyl-4,5-dehydro-L-proline 4.7 and N-Boc-4-propenyl-3,4-
dehydro-L-proline 4.7’. 1H NMR (400 MHz, MeOD) δ 6.26-5.91 (m, 1H), 5.81-5.55 (m, 
2H), 4.50-4.18 (m, 2H), 1.84 and 1.82 (s(2), 3H), 1.50 and 1.45 (s(2), 9H). 13C NMR 
(MeOD) δ 174.7 and 174.3, 141.0 and 140.0, 131.0 and 130.2, 125.9 and 124.1, 121.0, 
81.6, 68.5 and 67.9, 55.8 and 53.3, 28.8 and 28.6, 18.5 and 15.1. HRMS (FAB): m/z 
276.1213 (M+Na)+. Calcd for C13H19NO4 (M+Na)+: 276.1206.  
4-Propenyl-4,5-dehydro-L-proline 1.5. 1H NMR (400 MHz, MeOD) δ 6.33-5.99 
(dd, J=16, 12, 1H), 5.93-5.75 (m, 2H), 5.10 (s, 1H), 4.43-4.16 (m, 2H), 1.85 (s, 3H). 13C 
NMR (MeOD) δ 138.0, 132.7, 124.4, 121.8, 119.4, 67.4, 54.2, 15.4. HRMS (ESI+): m/z 
154.0862 (M+H)+. Calcd for C8H11NO2 (M+H)+: 154.0863. 
Adenylation activity. The adenylation assay was based on a radioactive assay 
reported previously.24 The SibDAT (0.25 µM) was incubated at 37 °C for 50 min with the 
putative amino acid substrate (0.8 mM) and cosubstrate ATP (3.7 mM) in HEPES (35 mM 
pH 7.5) along with TCEP (1.0 mM), MgCl2 (7.5 mM), glycerol (7.5% v/v), NaPPi (1.0 
mM) and [32P]-PPi (1 µCi). SibDC (0.25 µM) and SibDR (0.25 µM) was included in 
reaction mixtures testing for condensation and reductase domain effects. The 100 µL 
reaction was quenched with 400 µL 500 mM HClO4, chased with 400 µL 100 mM NaPPi 
and added to 200 µL 4% (w/v) activated charcoal. The charcoal was pelleted by 
centrifugation (14,000 rpm, 5 min) and washed 3x with 1 mL H2O. The charcoal was 
resuspended in 500 µL H2O and transferred into a scintillation vial containing 5 mL 
scintillation fluid. Radioactivity was measured using a scintillation counter. Negative 
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control reactions were conducted by either excluding SibDAT or the putative amino acid 
substrate. 
Thiolation activity. Pure SibDAT or an adenylation reaction mixture with SibDAT 
was denatured and then digested with trypsin according to the manufacturer’s (Promega) 
instructions at a final protease to protein ratio of 1:100 (w/w). The reaction, denaturation 
and digestion steps were performed at pH 7.0 to prevent base-catalyzed hydrolysis of the 
thioester group from the phosphopantetheinylated peptide of interest. The tryptically 
digested peptides were desalted using a ZipTip and separated by the UPLC-MS for analysis 
as described in the general methods. 
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4.5 4.1a  
N-Boc-L-DOPA 4.3. The synthesis was based on a reported protocol.96 L-DOPA 
(250 mg, 1.25 mmol) and Boc2O (278 mg, 1.26 mmol) were dissolved in 1,4-dioxane (2.50 
mL), H2O (1.25 mL) and NaOH (1.25 mL, 1 M). The reaction mixture was purged with N2 
(g) and stirred for 20 h in darkness at room temperature. The reaction mixture was acidified 
to pH 3 with H2SO4 (0.06 mL, 18 M) and extracted with EtOAc (3 x 3 mL). The organic 
fractions were combined, washed with H2O (3 x 3 mL) and brine (3 x 3 mL), dried over 
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Na2SO4 and evaporated under reduced pressure to yield a yellow oil (270 mg, 72% yield). 
1H NMR (300 MHz, DMSO-d6) δ 8.72 (bs, 1H), 6.93 (d, J=8.3, 1H), 6.65-6.56 (m, J=4.1, 
2H), 6.47 (J=7.9, 1H), 4.09-3.85 (m, 1H), 2.95-2.45 (m, 2H), 1.33 (s, 9H). 13C NMR 
(DMSO-d6) δ 173.8, 155.5, 144.9, 143.8, 128.7, 119.8, 116.5, 115.3, 78.1, 55.5, 36.0, 28.2. 
The crude product was used directly without purification in the next synthetic step. 
N-Boc-L-DOPA-thiophenol 4.4. Crude Boc-L-DOPA 4.3 prepared above (250 mg, 
1.25 mmol) was dissolved in anhydrous DMF (1.0 mL) and combined with PyBOP (674 
mg, 1.25 mmol) in anhydrous DMF (0.7 mL). This mixture was stirred for 10 min in 
darkness at room temperature under N2 (g). Benzenethiol (152 µL, 1.25 mmol) was injected 
into the reaction mixture and stirred for 1 h. K2CO3 (86 mg, 0.63 mmol, 0.5 eq.) was added 
and the reaction mixture was stirred for an additional 3 h. The reaction mixture was 
combined with 10 mM potassium phosphate pH 6.0 (2.3 mL) and extracted with EtOAc (3 
x 3 mL). The organic fractions were combined and evaporated under reduced pressure to 
yield a yellow oil. The oil was purified by silica gel radial chromatography (chromatotron) 
using a gradient of 30%-50% EtOAc in hexanes. The fractions containing desired material 
were evaporated under reduced pressure to yield a yellow oil (325 mg, 88% yield). Rf 0.4 
(40% EtOAc in hexanes). 1H NMR (300 MHz, CDCl3) δ 7.46-7.29 (bs, 5H), 6.79 (d, J=8.1, 
1H), 6.71 (d, J=1.5, 1H), 6.56 (d, J=7.5, 1H), 5.25 (d, J=8.7, 1H), 4.65 (m, 1H), 3.10-2.81 
(m, 2H), 1.45 (s, 9H) are consistent with published values.96 13C NMR (CDCl3) δ 200.0, 
155.4, 144.2, 143.3, 134.6, 129.4, 129.1, 127.5, 127.1, 121.3, 116.2, 115.3, 80.8, 60.6, 37.6, 
28.2 are consistent with published values.96 HRMS (ESI+): m/z 290.0850 (M-Boc+H)+. 
Calcd for C15H15NO3S (M-Boc+H)+: 290.0845. 
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L-DOPA-SNAC 4.1a. Boc-L-DOPA-thiophenol 4.4 (4.8 mg, 0.010 mmol) was 
dissolved in CH2Cl2 (0.1 mL) and treated with neat TFA (0.1 mL). The reaction mixture 
was stirred for 30 min in darkness at room temperature before it was placed under N2 (g) 
for 2 h. N-Acetylcysteamine (SNAC) (5.5 µL, 0.050 mmol) was dissolved in 10 mM 
potassium phosphate pH 8.0 (0.2 mL), added to the reaction mixture and stirred for 2.5 h 
in darkness at room temperature under N2 (g). The reaction was mixed with 5% CH3CN in 
10 mM aqueous ammonium formate (1.0 mL) and fractionated by analytical C18 RP-
HPLC as described in the general methods (5%-95% CH3CN gradient in 10 mM 
ammonium formate over 30 min, 1 mL/min). L-DOPA-SNAC 4.1a was collected (tr = 8.6 
min) and lyophilized to yield a white solid. 1H NMR (400 MHz, D2O) δ 6.88 (d, J=8.1, 
1H), 6.82 (d, J=2.3, 1H), 6.72 (dd, J=8.1, 2.0, 1H), 4.42 (t, J=7.9(2), 1H), 3.37 (m, 2H), 
3.21 (m, 2H), 3.08 (m, 2H), 1.95 (s, 3H). HRMS (ESI+): m/z 299.1068 (M)+. Calcd for 
C13H19N2O4S (M)+: 299.1060. λmax = 239 and 283 nm (diode array detector, 18% CH3CN 
in 0.1% formic acid). 




L-DOPA-pantetheine 4.1b. Boc-L-DOPA-thiophenol 4.4 (4.8 mg, 0.01 mmol) was 
dissolved in DMF (50 µL) and mixed with 20 mM potassium phosphate pH 8.0 (100 µL). 
The solution was treated with pantetheine dimethyl ketal (3.2 mg, 0.010 mmol) also 
dissolved in DMF (50 µL) and mixed with 20 mM potassium phosphate pH 8.0 (100 µL). 
The reaction mixture was stirred for 2.5 h in darkness at room temperature under N2 (g) 
and then treated with neat TFA (0.1 mL) before stirring for another 2 h in darkness at room 
temperature under N2 (g). The reaction was mixed with 5% CH3CN in 10 mM aqueous 
ammonium formate pH 4.5 (1.0 mL) and fractionated by analytical C18 RP-HPLC (5%-
95% CH3CN gradient in 10 mM ammonium formate over 30 min, 1 mL/min). L-DOPA-
pantetheine 4.1b was collected (tr = 9.0 min) and lyophilized to yield a white solid. HRMS 
(ESI+): m/z 458.1949 (M+H)+. Calcd for C20H31N3O7S (M+H)+: 458.1955. λmax = 243 and 














Chapter 5: SibB Promotion of SibD’s Adenylation Activity 
 
5.1 Introduction 
The success of PBD engineering in the future relies not only on deciphering the 
dihydropyrrole biosynthetic steps but also achieving industrial-scale (multi-gram per liter) 
production of the desired PBD.100 Improving the efficiency of biosynthetic enzymes is one 
strategy used to increase metabolite yields in engineered biosynthetic pathways.101-104 This 
also appears to be used by nature as illustrated by a growing number of MbtH-like proteins 
(MLPs), a class of protein that promote adenylation reactions catalyzed by NRPSs.105-112 
Specifically MLPs, designated as members of the MLP superfamily, form complexes with 
adenylation domains to increase amino acyl adenylate production. The mechanism for this 
is unknown although mutant proteins implicate involvement of a hydrophobic interface 
that forms once the MLP and adenylase associate.83,113-116 A search for an MLP in 
sibiromycin biosynthesis was undertaken by the prospect of increasing PBD yields in 
engineered pathways. 
None of the genes within the sibiromycin biosynthetic cluster had previously been 
predicted31 to code for proteins containing a Pfam domain (PF03621), a domain 
characteristic of MLP superfamily members. This domain contains three conserved 
tryptophans that are present within two universally conserved sequences (SϕWP and 
PXGW where ϕ represents an aliphatic amino acid such as I, L or V) and one moderately 
(75%) conserved sequence (WTDXRP).113 A recent BLAST search confirms that 
sibiromycin’s 26 biosynthetic proteins share no sequence homology with predicted or 
known MLPs (evaluating hits with expect values < 0.1). However, such a gene could reside 
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elsewhere on the genome, a phenomenon observed for MLP encoding genes involved in 
the biosynthesis of other natural products.99,117,118 However, locating an MLP in S. 
sibiricum would be difficult as its genome has not been sequenced. Although degenerate 
primers can amplify a target gene from genomic DNA via PCR, this technique is not 
amenable for MLP-encoding genes due to their low sequence homology. In some cases, 
MLPs from one biosynthetic pathway promotes an adenylation domain found in a 
biosynthetic pathway from another bacteria.119-123 Expanding the search for candidate 
MLPs in other bacteria that produce related natural products pointed to three possible 
candidates. 
Hormaomycin biosynthesis uses an MLP (HrmR) to activate the activity of all the 
adenylases embedded within its two NRPSs.90 The adenylation domain in the third module 
of one of its NRPSs (HrmPA3) co-expresses with HrmR and adenylates 4-(Z)-
propenylproline (Scheme 5-1), a pyrrolidine moiety synthesized similarly to the 
dihydropyrrole moiety in sibiromycin.90 In addition, HrmR appears to be a promiscuous 
MLP, activating seven adenylases with seven structurally distinct substrates. These two 
features make HrmR an attractive candidate for promoting SibD’s adenylation activity. 
 
 
Scheme 5-1. The adenylation domain in the NRPS involved in hormaomycin’s pyrrolidine 
biosynthesis (HrmPA3) catalyzes the adenylation of 4-(Z)-propenylproline only in the 
presence of HrmR, an MLP. 
 
Mining the genomes of other PBD producers presents an opportunity to find 
additional candidates. However, none of the sequenced genes from the remaining related 
natural products (tomaymycin, anthramycin, porothramycin, tilivalline or lincomycin A) 
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are thought to code for MLPs and like sibiromycin, the genomes of their producers have 
not been sequenced. Instead, the Antibiotics & Secondary Metabolite Analysis Shell 3.0 
(antiSMASH) program,124 designed to find related biosynthetic gene clusters, was used to 
locate a new one in Nocardia brasiliensis (Figure 5-1), a fully sequenced human pathogen. 
Two MLP-encoding genes (NCBI accession numbers WP_014988415 and 
WP_011207082) were found outside that gene cluster and added to the list of candidates. 
 
 
Figure 5-1. Newly identified PBD biosynthetic gene cluster in N. brasiliensis ATCC 
700358 (GenBank accession number NC_018681). 
 
One last protein was added to the list upon performing a rudimentary analysis of 
non-MLP proteins associated with sibiromycin biosynthesis. In rubradirin biosynthesis, a 
180 amino acid domain devoid of consensus sequence signatures of MLPs still activates 
its downstream adenylation domain.125  Neither the SibDC nor SibDR domains cause an 
observable effect on SibDAT’s adenylation activity (Chapter 4) so different proteins within 
the sibiromycin biosynthetic pathway with no known function (SibB and SibR) were 
considered instead. SibB was a promising candidate as its encoding-gene (sibB) is expected 
to code for a small (93 aa) protein similarly sized to MLPs (~ 70 aa). Thus SibB was 
included in the list of candidates. According to BLAST analysis, SibB shares no sequence 
homology with MLP superfamily members. Although SibB has three tryptophans, none of 
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them are found in the same conserved sequences observed in MLPs. The SibB amino acid 
sequence shares low sequence similarity (<10%) with MLPs HrmR, WP_014988415 and 
WP_011207082. 
The search for possible promoters of adenylation by SibD led to four possible 
candidates (HrmR, WP_014988415, WP_011207082 and SibB). Each protein was 
produced and then assayed to see if any could promote adenylation of L-tyrosine, a model 
substrate of SibDAT. In addition, these proteins were assayed to determine if any could 
activate the adenylation of one of the other dihydropyrrole pathway intermediates, 
previously (Chapter 4) not adenylated by SibDAT. 
5.2 Results and Discussion 
Production of MLPs. MLP coding genes that had been synthesized and optimized 
for expression in E. coli (GenScript) were subcloned into the pTYB12 vector. Each MLP 
fused with an N-terminal chitin binding domain-intein tag (CBD-intein) was expressed in 
BL21(DE3) E. coli. They were purified via chitin binding affinity chromatography. The 
tag was removed from the protein by DTT-induced CBD cleavage that resulted in a 
conformation change triggering intein cleavage. The final purification step provided ca. 8, 
4, and 21 mg of HrmR, WP_014988415 and WP_011207082, respectively, per liter of 
growth media (Appendix D-1 and D-2). Use of this purification tag was favored over the 
His6-SUMO tag as the latter tag would pass its serine residue onto the N-terminus of the 
MLP. Any non-native residue has the potential to disrupt protein-protein interactions 
between each candidate MLP and SibDAT, and thus non-native residues were avoided. 
Production of SibB. The CBD-intein tagged SibB was expressed both in 
BL21(DE3) and Rosetta2 E. coli. The Rosetta2 strain is a derivative of the BL21(DE3) E. 
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coli strain that supplies additional tRNA codons rarely used by E. coli but present in the 
SibB amino acid sequence. Both sets of the fusion protein bound the chitin resin but in both 
cases, DTT treatment did not elute SibB from the resin based on SDS-PAGE analysis of 
the elution fraction. The likely explanation is that the protein misfolds during expression, 
consistent with a failed attempt to produce soluble native SibB without purification tags. 
Instead, soluble SibB was expressed as a fusion with an N-terminal His6-SUMO tag in 
Rosetta2 E. coli and purified via Ni-NTA affinity chromatography using imidazole (250 
mM) as the eluant. The tag was removed by Ulp1. SibB was separated from the free His6-
SUMO tag via a second round of Ni-NTA affinity chromatography. The final purification 
step provided ca. 0.5 mg of protein per liter of growth media (Appendix D-3). SibB 
precipitated at concentrations higher than 0.1 mg/mL. This instability precluded use of size 
exclusion chromatography to obtain homogenous protein with respect to its oligomeric 
states as this step requires the application of a low volume of highly concentrated protein. 
SibB promotes SibDAT adenylation activity. The effects of each MLP and SibB 
on L-tyrosine adenylation by SibDAT were tested using the ATP-[32P]PPi exchange assay 
(Scheme 5-2 and Figure 5-2). Addition of four molar equivalents of each of the three 
candidate MLPs to one molar equivalent of SibDAT during L-tyrosine adenylation did not 
increase the radiolabel incorporated into ATP compared with equivalent reactions lacking 
the MLP. All three MLPs consequently did not promote adenylation by SibDAT. Addition 
of four molar equivalents of SibB in the equivalent adenylation reaction increased [32P]-
ATP yield nearly 6-fold (Figure 5-2). Analogous results were obtained when the substrate 
L-tyrosine was replaced with L-threonine, a non-native substrate of SibDAT (Figure 5-3). 
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This provided the first in vitro evidence that SibB promoted the adenylation reaction of 
SibDAT. 
 
Scheme 5-2. Radioactive L-tyrosine adenylation assay that monitors amino acyl-adenylate 
formation indirectly though the reversible exchange of [32P]PPi with ATP followed by the 
capture of the resulting [32P]ATP onto charcoal. 
 
 
Figure 5-2. Effect of putative adenylase protein promoters on L-tyrosine adenylation by 
SibDAT assessed by the ATP/[32P]PPi exchange assay. Each measurement represents the 
average of three independent trials. The error bars represent one standard deviation of 
uncertainty. 
 
All the available sibiromycin dihydropyrrole pathway compounds and analogs 
were retested as substrates for adenylation by SibDAT in the presence of each MLP and 
SibB. With the exception of L-tyrosine and L-threonine, the remaining compounds treated 
with SibDAT did not increase the radiolabel incorporated into ATP compared with 
equivalent reactions lacking the MLP or SibB (Figure 5-3). L-tyrosine and L-threonine 
























promoted SibDAT adenylation of L-threonine and L-tyrosine, evident by an increase of 
radiolabel incorporation into ATP compared with equivalent reactions lacking SibB. 
Detection of a His6-SUMO-SibB and SibDAT complex. Decreasing the molar 
equivalents of SibB used from four to one in the L-tyrosine adenylation reaction described 
above resulted in a 54% drop in the level of radiolabel incorporation into ATP. A 
comparable result was observed with an MLP (NocI) that promotes multiple NRPS-
catalyzed adenylation reactions during the assembly of the natural product nocardicin A.99 
NocI, representative of MLPs from other biosynthetic pathways, forms a protein complex 
with the NRPS,99 suggesting SibB probably forms a protein complex with SibDAT as well. 
If SibB relies on strong protein-protein interactions with SibD for proper function, SibDAT 
might be expected to co-purify with SibB upon their co-expression. To test this theory, 
SibDAT, as a fusion with an N-terminal His6-SUMO tag, was co-expressed with native SibB 
in E. coli. The expressed proteins were purified via Ni-NTA chromatography, incubated 
with Ulp1 to remove the His6-SUMO tag and purified further via size exclusion 
chromatography. However, the eluate produced by both chromatographic steps consisted 
of His6-SUMO-SibDAT but not SibB, as determined by gel electrophoresis. An aliquot of 
the purified protein sample was denatured, digested with trypsin and subjected to UPLC-
MS analysis. Only peptides derived from SibDAT were detected. It is likely that E. coli 
expressed an improperly folded SibB that is incapable of binding SibDAT. The propensity 
for native SibB to misfold is supported by our earlier finding that SibB precipitates after 
removal of the His6-SUMO tag. Improper folding of SibB also offers an explanation as to 





Figure 5-3. Probing for putative substrate activation by the adenylation domain in SibDAT 
in the presence of SibB determined by the ATP/[32P]PPi exchange assay. Each 
measurement represents the average of three independent trials. The error bars represent 
one standard deviation of uncertainty. 
to the quaternary structure of the protein. It is also possible that the co-purification 
conditions inhibited the protein-protein interactions necessary to form the protein complex. 
Since we were unable to detect the protein complex in vivo, an in vitro approach 
was used instead. A binding assay was devised to see if the stable His6-SUMO-SibB could 
act as a ‘bait’ protein and bind SibDAT, the anticipated ‘prey’ protein. The ratio of His6-
SUMO-SibB and SibDAT in the protein complex was investigated more rigorously testing 
various molar equivalents of SibDAT (Figure 5-4). At least up to four molar equivalents 
SibDAT in the presence of one molar equivalent of His6-SUMO-SibB bound the nickel 
chelate resin. The two proteins co-eluted in cleavage buffer consistent with protein-protein 






















bind the nickel chelate resin in the absence of His6-SUMO-SibB. Although the results 
suggest that SibD and SibB form a protein complex at a 4:1 ratio, this ratio remains 
speculative without knowledge of the oligomeric states of SibDAT and SibB. During its 
purification, SibDAT eluted from the size exclusion chromatography column as multiple 
peaks suggesting SibDAT exists in multiple oligomeric states. It is unclear if this 




























































































































Figure 5-4. SDS-PAGE gel image of fractions from the in vitro binding assay to detect 
binding between SibDAT and His6-SUMO-SibB. SDS-PAGE gel of the eluate consisting 
of the bait protein His6-SUMO-SibB and the prey protein SibDAT loaded after application 
onto a Ni-NTA agarose column and elution with sodium phosphate buffer containing 
imidazole (250 mM). Mixtures of SibDAT to His6-SUMO-SibB at a range of molar ratios 
were incubated together at 4 °C for 12 min prior to column loading. 
 
Prediction of residues expected to constitute the SibB-SibD interface. The 
functional similarity between SibB and MLPs raises a possibility that they share a similar 
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mode of action. Crystal structures and sequence alignments of MLP-dependent adenylases 
from NRPSs indicate a conserved alanine or proline interacts with a hydrophobic cleft on 
the MLP composed of a conserved tryptophan dyad.113,114 In contrast, the MLP-
independent adenylases carry other amino acids at this site.116 The adenylation domains in 
HrmP and LmbC, related to the adenylation domain in SibD, conform to this trend. HrmP 
contains an MLP-dependent adenylase90 in its third module with an alanine (A2977) 
expected to interact with the MLP while LmbC is an MLP-independent standalone 
adenylase89,126,127 with a threonine (T376) at the equivalent position (Figure 5-5). A proline 
occupies the same position in SibD (P887), initially suggesting it was an MLP-dependent 
protein. SibD deviates from the trend as it invokes the action of SibB, a non-MLP, to 
promote the adenylation reaction. P887 in SibD is conserved in other PBD synthesizing 
homologs TomB (P1012), Orf22 (P930), Por21 (P837) as well as the homolog (NCBI 
accession number WP_014985045) in the putative PBD producer N. brasiliensis (P815). 
By extrapolation, their adenylation reactions are expected to be promoted by similar 
proteins. In contrast, the SibD homolog NpsB predicted to assemble the PBD tilivalline 
likely catalyzes its adenylation reaction without using another protein as a serine (S844) is 
present instead of the proline. The three tryptophans present in SibB could form the 
hydrophobic interface and interact with the P887 in SibD although mutagenesis 
experiments are necessary to validate the requirement and role of all the aforementioned 
residues.  
The in vitro studies show that SibB promotes the adenylation of L-tyrosine by 
SibDAT. Blast analysis of SibB reveals that homologs are coded by genes in the pathogen 




SibD            QRPV-PFGVRGELYVGGPVVGRGYLHLPDQTRERFRPDPYAGRPGGRMYRTGDL  904 
TomB            RELL-PPGVTGELYIGGPYLSPGYRGRLEETARRFLPDPYGG-DGEVIYRTGDL 1028 
Orf22           DEPA-PFGVEGELCVAGPVVSPGYIGLPEKTRQAMVPDPFV--PGQLMYRTGDV  945 
Por21           AQRA-PFGVDGELCVAGPVVSPGYIGLPEKTSRAMVPDPFV--PGQLMYRTGDI  852 
WP_014985045    AQRV-PFGVEGELCVAGPVISPGYLGLPEKTREAMVPDPFV--AGQLMYRTGDV  830 
NpsB            LQLV-PAGVAGELLIVSDFLSPGYHNKSEESARRFISAEGFATQSCHAYRTGDL  861 
LmbC            GRPVDAVGSVGELVVAGPTVAAGYWGVEGHGAERFRTGETC--PGGRAYATGDQ  391 
HrmPA3          LQAV-PPGVPGELCIAGPQLARGYLGRPGTTAERFVADPFGP-SGARMYRTGDR 2993 
               . *  *** : .  :. **          : .       .   * *** 
 
Figure 5-5. Sequence alignment of SibD with biosynthetically relevant homologs. Any 
proline or alanine at the highlighted position is predicted to interact with an MLP.116 The 
NCBI accession number of SibD homolog suspected of producing the PBD in N. 
brasiliensis is written as this protein remains unnamed. The last residue shown is numbered 
on the right. 
 
producer Streptomyces globisporus (NCBI accession number WP_030583800) but none 
appear in other PBD biosynthetic pathways. However, functionally similar proteins may 
exist as the anthramycin gene cluster contains genes predicted to code for small proteins 
(89 aa length for Orf11 and 58 aa length for Orf18) and the putative PBD gene cluster in 
N. brasiliensis contains a gene predicted to code for a small protein (62 aa length for 
WP_014985041), all of unknown function. 
5.3 Summary 
 The sibB gene, present within the sibiromycin biosynthetic gene cluster, codes 
for a small protein. Its role was not known until now. SibB promotes the adenylation 
activity of SibDAT. His6-SUMO-SibB co-elutes with SibDAT suggesting SibD recruits 
SibB in vivo to form a functionally active protein complex. SibB’s promotion of 
adenylation activity is likely enhanced in the presence of SibD’s unknown native 
substrate. Although SibB behaves similarly to MLPs, differences in their primary 
sequences expands the list of adenylase promoters. MLPs known (HrmR) or expected 
(WP_014988415 and WP_011207082) to promote adenylation reaction during assembly 
of related natural products did not replace SibB functionally. 
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5.4 Experimental Procedures 
 Materials. The pTYB12 plasmid and chitin resin were obtained from New 
England Biolabs (Ipswich, MA). The Pierce BCA protein assay kit was obtained from 
Thermo Scientific (Grand Island, NY). A HiTrap chelating HP column was obtained from 
GE Healthcare (Piscataway, NJ). The Coomassie Brilliant Blue G-250 protein stain 
powder was obtained from Bio-Rad (Hercules, CA). All other relevant materials are 
described in previous chapters. 
 General methods. A 15% resolving acrylamide layer was used to separate 
small (<15 kDa) proteins by SDS-PAGE for analysis of expression and purification. 
Protein samples from in vitro protein-protein binding assays were visualized after SDS-
PAGE by staining the gel with colloidal-based Coomassie dye using a protocol128 in 
which ethanol replaced methanol in the solvent. Sequence alignments were generated 
using the Multiple Sequence Comparison by Log-Expectation (MUSCLE) program.129,130 
All other relevant general protocols are described in previous chapters. 
 Cloning of the MLP-coding and sibB genes. The nucleotide sequence used to 
express HmrR previously90 was synthesized (GenScript) and cloned into the pUC57-Kan 
plasmid flanked by 5’-NcoI and 3’-HindIII restriction sites (GenScript). Non-native 5’-
CG bases were included to keep the codons in-frame with the upstream start codon. The 
hrmR gene from the pUC57/hrmR vector was subcloned into the first multiple cloning 
site in the pACYCDuet-1 plasmid (Novagen) using the 5’-NcoI and 3’-HindIII restriction 
sites to generate pACYCDuet-1/hrmR. The hrmR gene was amplified from the 
pACYCDuet-1/hrmR vector using a forward primer of 5’-
AAAAAAGAATGCTCGAGATCGAGAAAAGAATGGA-3’ and a reverse primer of 
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5’-AAAAAACTCGAGTCATGCCGCGCTCCCTTC-3’. The PCR product was gel 
purified. The genes encoding WP_014988415 and WP_011207082 were each 
synthesized (GenScript) with codons optimized for expression in E. coli (Appendix D-
4) and cloned into the pUC57-Kan plasmid flanked by 5’-BsmI and 3’-XhoI restriction 
sites (GenScript). For both genes, a non-native 5’-T base was included to keep the codons 
in-frame with the upstream start codon of its destination vector (GenScript). The gene 
encoding SibB was amplified from the pSuperSib131 cosmid using a forward primer of 
5’-AATTAATGAATGCTACCCGGACCGCCTCGC-3’ and a reverse primer of 5’-
AATTAATCTCGAGCTACAGCCACCCGGGC-3’ and the PCR product was gel 
purified. All four genes were digested with BsmI and XhoI restriction enzymes and each 
ligated with the linearized pTYB12 plasmid to generate pTYB12/hrmR, pTYB12/ 
wp_014988415, pTYB12/wp_011207082 and pTYB12/sibB. The genes each contained 
chitin binding domain encoding gene fragment within an intein encoding gene fragment 
on the 5’ side of the gene. 
Subcloning of the sibB gene. The gene encoding SibB was amplified from the 
pSuperSib131 cosmid using a forward primer of 5’-
AATTAAAGGATCCACCCGGACCGCCTCGC-3’ and a reverse primer of 5’-
AATTAAAAAGCTTTCACAGCCACCCGGGCGC-3’. The PCR product was gel 
purified and digested with BamHI-HF and HindIII restriction enzymes. It was ligated with 
the linearized pSMT3 plasmid to generate pSMT3/sibB. 
Subcloning of the sibB gene into a co-expression vector. The gene encoding SibB 
was amplified using 5’-BsmI-sibB-XhoI-3’ as a template that was previously amplified, 
purified and digested as described above. A forward primer of 5’-
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AATTAAACCATGGGCACCCGGACCGCCTCGC-3’ and a reverse primer of 5’-
AATTAAAAAGCTTTCACAGCCACCCGGGCGC-3’ were used in the PCR reaction. 
The resulting PCR product was gel purified, digested with NcoI and HindIII restriction 
enzymes and ligated with the linearized pACYCDuet-1 plasmid into the first multiple 
cloning site to generate pACYCDuet-1/sibB. 
 Expression of proteins. Expression was carried out under similar conditions 
described in Chapter 2 except for the following changes. E. coli cultures transformed with 
the pTYB12-based plasmids were supplemented with ampicillin (100 µg/mL) instead of 
kanamycin (50 µg/mL). The pTYB12/sibB and pSMT3/sibB were each transformed into 
Rosetta2(DE3) and their cultures were supplemented with ampicillin (50 µg/mL) and 
kanamycin (25 µg/mL), respectively. An additional antibiotic, chloramphenicol (17 
µg/mL) was included in the Rosetta2(DE3) cell cultures. Cell cultures transformed with 
pTYB12-based plasmids were induced with IPTG (500 µM) while the cell cultures 
transformed with pSMT3/sibB were induced with IPTG (50 µM). Inductions were 
performed at 16 °C and the induction time was shortened to 4 h for WP_011207082 
compared with 12 h for the remaining proteins. Co-expression of His6-SUMO-SibDAT 
with SibB was carried out under identical co-expression conditions described in Chapter 
4. 
Purification of proteins. All purification steps were performed at 4 °C. Cells 
alternatively expressing CBD-intein-HrmR, CBD-intein-WP_014988415, CBD-intein-
WP_011207082 or CBD-intein-SibB were resuspended in resuspension buffer (20 mM 
Tris pH 8.0, 500 mM NaCl, 1 mM EDTA and 1 mM fresh TCEP). The cells were lysed by 
four passages through an EmulsiFlex homogenizer at 15,000 psi. Cell debris was removed 
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by centrifugation at 40,000 x g (60 min) and the supernatant was loaded onto a chitin resin 
(10 mL) column pre-equilibrated with wash buffer (50 mM Tris pH 8.0, 50 mM NaCl, 10% 
glycerol and 1 mM fresh TCEP). The resin was washed with wash buffer, resuspended in 
cleavage buffer (100 mM DTT in wash buffer) and incubated at 4 °C for three days to 
remove the intein tag by proteolysis. The protein was eluted with cleavage buffer via 
gravity. High molecular weight impurities were removed using an Amicon ultra centrifugal 
filter at 5,000 rpm with a membrane (30,000 NMWL). The protein in the filtrate was 
concentrated in an Amicon ultra centrifugal filter at 5,000 rpm with a membrane (3,500 
NMWL). Protein solutions in gel filtration buffer were flash frozen in droplets with N2 (l) 
and stored at -80 °C until needed. The attempted co-purification and purification of His6-
SUMO fusion proteins were carried out under similar conditions for purification of SibDAT 
described in Chapter 4 except for the following changes. SibB was susceptible to 
aggregation after its His6-SUMO tag was removed so SibB was concentrated in an Amicon 
ultra centrifugal filter with a membrane (3,500 NMWL) only to < 0.2 mg/mL because SibB 
precipitated at higher concentrations. All isolated proteins were ≥ 95% pure as estimated 
by visual inspection after their separation by denaturing gel electrophoresis and staining 
with Coomassie Brilliant Blue. 
Adenylation activity. The adenylation assay was monitored under identical 
conditions described in Chapter 4. An MLP or SibB (1 µM) was included in the reaction 
mixture. 
 Protein-protein binding assay. His6-SUMO-SibB and SibDAT were quantified 
using the BCA protein assay kit. A mixture of both proteins at the indicated ratios in wash 
buffer (50 mM sodium phosphate pH 8.0, 175 mM NaCl, 10% glycerol and 1 mM fresh 
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TCEP) was loaded onto a Hi-Trap chelating HP (1 mL) column charged with Ni2+ and pre-
equilibrated with wash buffer. The resin was washed with wash buffer (5 CV) before the 
protein complex was eluted with elution buffer (1.5 CV) (50 mM sodium phosphate pH 
8.0, 300 mM NaCl, 250 mM imidazole, 10% glycerol and 1 mM fresh TCEP). The eluate 
from the wash (3.0 mL) and elution (1.5 mL) steps were concentrated to 150 µL in an 
Amicon ultra centrifugal filter (3,000 NMWL) at 13,000 rpm. The protein in each 
concentrated sample was separated by SDS-PAGE and visualized by staining the gel with 


















Chapter 6: Conclusions 
 
The ultimate goal of studying PBD dihydropyrrole biosynthesis is to engineer new 
drugs capable of alkylating DNA and evading DNA error-correcting proteins. This work 
focused on the production and study of biosynthetic enzymes that are thought to be 
common in the formation, modification and assembly of the dihydropyrrole moiety within 
PBDs. 
Unwanted byproducts and competing pathways are always issues of concern in 
engineered pathways.100 For example, extradiol dioxygenases such as L-DOPA 
dioxygenases have the potential to cleave their catechols at multiple sites to form multiple 
acyclic compounds. The acyclic compounds themselves can then cyclize into multiple 
compounds. However, only a single regiochemistry is promoted by SibV and its homolog 
Orf12 to establish the dihydropyrrole scaffold 1.1 from L-DOPA. The lability of 1.1 (t1/2 of 
36 h at 25 °C) indicates that the next step in the engineered pathway must be efficient to 
avoid decomposition of this key pathway intermediate. 
Maximizing product yields is crucial for engineered pathways to become the source 
of pharmaceuticals. The ability for MLPs to promote adenylation activity of NRPSs 
prompted a search for a functionally similar protein involved in sibiromycin biosynthesis. 
SibD catalyzed adenylation is promoted by SibB, a previously uncharacterized protein. 
Engineered pathways, particularly those based on PBDs that lack the SibB homolog may 
benefit by incorporating sibB into the gene cluster. This also encourages the search for 
functionally similar proteins beyond MLPs in other natural product biosynthetic pathways. 
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Before engineering efforts may begin, the function and/or substrates of many 
biosynthetic enzymes still need to be identified. SibS’s affinity for 1.1 (KD = 64 ± 2 µM) 
supports its involvement in dihydropyrrole biosynthesis. However, the absence of 
observable hydrolase activity with SibS and methyltransferase activity with SibZ indicate 
that modifications to the dihydropyrrole scaffold are more complex than initially proposed. 
The ability for SibD to adenylate and thiolate L-tyrosine but not the final dihydropyrrole 
moiety 1.5 also indicates that the proposed pathway needs revision. The following 
hypotheses aim to provide alternative steps that are consistent with prior knowledge of the 
pathways and findings in this work. 
Hydrolysis and methylation of 1.1 are catalyzed by a protein complex. One 
possible revision of the pathway involves formation of a protein complex including SibT, 
conserved throughout the biosynthetic pathways, to catalyze the hydrolysis and 
methylation of 1.1. The use of a complex, although unprecedented for these types of 
reactions, could account for the absence of activity observed for reaction mixtures with 
SibS and/or SibZ. Upon formation of 1.1, a complex of SibS, SibZ and SibT are proposed 
to hydrolyze and methylate 1.1 to 1.3 (Scheme 6-1). SibS and SibZ are still expected to 
participate in these reactions based on SibS’s affinity for 1.1 and the SAM-binding motif 
in SibZ’s amino acid sequence. In the presence of the requisite F420-GluN cofactor, SibT 
is still proposed to reduce 1.3 to 1.4.31 These steps are consistent with the accumulation of 
1.3 in the absence of the F420-GluN cofactor in a mutant strain of the lincomycin A 
producer.42 
SibD is then proposed to adenylate and acylate 1.4. Enzymes unique to each 
dihydropyrrole and pyrrolidine pathway are proposed to catalyze reactions with the 
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acylated 1.4 (1.4-S-SibD). For example, SibW in sibiromycin is proposed to catalyze an 
oxidation to form 1.5-S-SibD. This accounts for the inability for SibD to adenylate or 
thiolate 1.5. Once formation of the dihydropyrrole moiety is complete, the condensation 
and reductase domains of SibD are proposed to incorporate it into the natural product. 
Testing this hypothesis minimally requires the production of SibT, SibY and SibW and the 
synthesis of 1.4. 
 
 
Scheme 6-1. Dihydropyrrole biosynthetic pathway in sibiromycin proposed based on the 
findings in this work. 
 
All biosynthetic steps occur with compounds loaded on the NRPS. An 
alternative revision of the pathway involves SibD-catalyzed adenylation and thiolation of 
L-tyrosine observed in vitro. All the dihydropyrrole biosynthetic enzymes are then 
proposed to catalyze reactions with substrates conjugated to the ACP (Scheme 6-2). Thus, 
SibU, SibV, SibS, SibZ, SibT and SibW are proposed to catalyze reactions with 
biosynthetic intermediates that are loaded onto SibD. If this is correct, this would be the 
first reported example of a hydrolase and C-methyltransferase capable of processing 
substrates that are loaded on an ACP. SibS and SibZ were unable to process 1.1-SNAC 
although these thioester substrate analogs often fail to replicate activity observed with their 
native NRPS counterparts.96 
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Scheme 6-2. An alternative biosynthetic pathway for dihydropyrrole moiety in 
sibiromycin. 
 
An alternative pathway that involves depurination and use of a protein 
complex. Both proposals discussed above dismiss SibS’s ability to depurinate SAM as an 
unproductive reaction. Although the SibS-catalyzed depurination of SAM does not have 
an obvious place in the biosynthesis of PBDs, it resembles a step during the biosynthesis 
of phosphate in E. coli derived from methylphosphonate.131 Specifically, PhnI catalyzes 
the depurination of ATP to form a ribosyl derivative that is then ligated to 
methylphosphonate by action of an enzyme complex, PhnGHL (Scheme 6-3). By analogy, 
some of dihydropyrrole biosynthetic intermediates may exist as ribose intermediates as 
well (Scheme 6-3). This could involve the displacement of adenine with 1.1 on a ribose 
derivative. To verify this theory, SAM or another donor such as ATP will need to provide 
the ribose acceptor in the presence of a protein complex that transfers 1.1 onto the ribose 
derivative. Candidates for the protein complex include SibS, SibZ and SibT common in 




Scheme 6-3. The formation of phosphate proceeds via the PhnI-catalyzed depurination of 
ATP to form a ribosyl group. The PhnGHL enzyme complex catalyzes the transfer of 














































Scheme 6-4. An alternative dihydropyrrole biosynthetic pathway in sibiromycin that 
accounts for the SibS-catalyzed depurinase activity in analogy to PhnI-catalyzed 
depurinase activity. To extend the analogy, this pathway needs an enzyme complex to 
catalyze the transfer of 1.1 onto the ribosyl acceptor where SibZ can methylate the vinyl 
group and subsequent enzymes can further tailor the dihydropyrrole ring. 
 
The search for genes involved in PBD biosynthesis outside of the gene cluster. 
The search for MLPs inadvertently led to the discovery of a new PBD gene cluster in N. 
brasiliensis. N. brasiliensis not only has the genetic potential to express a PBD, it has a 
fully sequenced genome unlike the other PBD producers. This facilitates the search for 
biosynthetically relevant genes missing within the PBD gene cluster. For example, the 
assignment of SibS as a hydrolase remains speculative, especially given its absence in 
hormaomycin biosynthesis, so other hydrolases predicted to be coded for by genes outside 
the gene cluster could be assayed for activity. In addition, the gene that codes for the 
phosphopantetheinyl transferase is missing in all PBD gene clusters but present in N. 
brasiliensis outside its PBD gene cluster (NCBI accession number WP_041564023). This 
gene is expected to code for the protein that post-translationally modifies the thiolation 
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domains of NRPSs responsible for assembling the PBDs. Testing of such genes will be 






























Figure A-1. SDS-PAGE gel images of PBD dioxygenases A) Orf12 and B) SibV at various 






Figure A-2. The oligomeric state of SibV was determined by size exclusion 
chromatography. The experimentally determined partition coefficient Kav of SibV, 
illustrated in blue, was superimposed onto the calibration curve, illustrated in red. 
Molecular weight standards ribonuclease A (13.7 kDa), ovalbumin (44.0 kDa), conalbumin 
(75.0 kDa) and aldolase (158.0 kDa) were used to establish the calibration curve. 
 





















Figure A-3. UV-visible spectra during dioxygenation of L-DOPA catalyzed by SibV at the 
indicated pHs. Reaction between L-DOPA (1.0 mM) and SibV (4.9 µM) was performed in 
sodium phosphate (250 mM) at pH 6.0, 7.0 and 8.0 or glycine-NaOH (250 mM) at pH 9.0. 
Scans were recorded every 20 sec for a total of 120 sec. The Amax at 414 nm increased and, 















































































































Figure A-4. Annotated COSY (400 MHz, 10% D2O, H2O suppression) spectrum of 1.1 











Figure A-5. Annotated 1H NMR (400 MHz, 10% D2O, H2O suppression with 




Figure A-6. UV-visible spectra monitoring interconversion of 1.1 and L-secodopa, the 
reversible hydrolysis product formed under acidic conditions. A) Absorbance spectra were 
recorded when no more changes were observed after 1.1 (7.5 µM) was incubated at 
indicated pHs. Each absorbance spectrum represents an average of three independent 
determinations. B) 1.1 (15.0 µM) in sodium phosphate (20 mM) at pH 8.0 was acidified to 
pH 4.0 and re-exposed to pH 8.0 to confirm the reversibility of the hydrolysis reaction. 














































































Figure A-7. Annotated 1H NMR spectrum of L-secodopa formed by acid-catalyzed 
hydrolysis of 1.1 (400 MHz, 10% D2O, H2O suppression with presaturation). The inset 
shows a UV-visible spectra of L-secodopa and its decomposition at 1 h intervals including 
spectra, indicated in blue and red, that show the state of L-secodopa during the first and last 








Figure A-8. UV-visible spectra during dioxygenation of L-DOPA catalyzed by Orf12 
under the indicated pH conditions. Reaction between L-DOPA (1.0 mM) and Orf12 (4.9 
µM) was performed in sodium phosphate-citrate (250 mM) at pH 5.0, sodium phosphate 
(250 mM) at pH 6.0 and 7.0 or glycine-NaOH (250 mM) at pH 9.0. Scans were recorded 
every 20 sec for a total of 120 sec. The Amax at 414 nm increased and, when detected, the 




Figure A-9. Lifetime of 1.1 determined by visible spectroscopy. A) UV-visible spectra of 
1.1 (20 µM) measured at 2 h intervals for 24 hours at 25 °C in sodium phosphate (20 mM) 
at pH 8.0. Each scan represents the average of three independent trials. B) A414 nm vs. time 
at 25 and 37 °C as measured from the spectra in (A). Each data point represents an average 
absorbance value at 414 nm. The error bars represents one standard deviation of 





























































































































kdecay at 25 °C = 0.019 + 0.003 hr
-1




Appendix B. Supporting Information for Chapter 3 
 
 
Figure B-1. SDS-PAGE gel images of A) SibS B) TomK and C) SibZ at various 





























































































































Figure B-2. Annotated A) 1H NMR spectrum, B) 13C NMR spectrum, C) COSY, D) HSQC 
and E) HMBC of N-Boc-4-triflate-4,5-dehydro-L-proline methyl ester 3.2 and N-Boc-4-
triflate-3,4-dehydro-L-proline methyl ester 3.2’ in CDCl3. 
 
Table B-1. 13C and 1H NMR of N-Boc-4-triflate-4,5-dehydro-L-proline methyl ester 3.2 
and N-Boc-4-triflate-3,4-dehydro-L-proline methyl ester 3.2’. 
 
Position 13C shift (ppm) 1H shift (ppm) HMBC Connectivity 
3.2 3.2’ 
2 2 63.7, 63.1 
5.08, 5.01 (t(2), 
1H) 
3, (4, 4), 5 
3 5 50.3, 50.0 
4.47-4.22 (m, 
J=14, 6.3, 2H) 
3, (4, 4), 5, (8, 8) 
4 4 146.3, 145.8  (2, 2), 3, 5 
5 3 111.3, 111.1 
5.75, 5.71 (s(2), 
1H) 
(2, 2), 3, 5 
7 7    
8 8 169.6, 169.3  (3), (9, 9) 
9 9 52.8, 52.6 
3.80, 3.78 (s(2), 
3H) 
(8, 8) 
10 10    
11 11 81.5, 81.4  (12, 12) 
12 12 28.3, 28.2 
1.49, 1.44 (s(2), 
9H) 
(11, 11), (12, 12) 
 
 











































Figure B-3. ESI+-MS of N-Boc-4-triflate-4,5-dehydro-L-proline methyl ester 3.2. The 








































































































































































Figure B-4. Annotated A) 1H NMR spectrum, B) 13C NMR spectrum, C) COSY, D) HSQC 
and E) HMBC of N-Boc-4-vinyl-4,5-dehydro-L-proline methyl ester 3.3 and N-Boc-4-
vinyl-3,4-dehydro-L-proline methyl ester 3.3’ in CDCl3. 
 
Table B-2. 13C and 1H NMR of N-Boc-4-vinyl-4,5-dehydro-L-proline methyl ester 3.3 and 
N-Boc-4-vinyl-3,4-dehydro-L-proline methyl ester 3.3’. 
 
Position 13C shift (ppm) 1H shift (ppm) HMBC Connectivity 
3.3 3.3’ 
2 2 66.8, 66.4 
5.09, 5.01 (s(2), 
1H) 
3, 5 
3 5 52.2, 52.0 
4.45-4.24 (m, 
2H) 
(2, 2), 3, (4, 4), 5, (6, 6), 
(8, 8) 
4 4 140.9  3, 5, (6, 6), (7, 7) 
5 3 122.1, 121.8 
5.68, 5.63 (s(2), 
1H) 
(2, 2), 3, 5, (6, 6) 
6 6 130.0, 129.8 
6.50-6.38 (m, 
1H) 
(3, 3) , (4, 4), (5, 5), (7, 
7) 
7 7 118.2, 117.7 
5.32-4.98 (m, 
2H) 
(4, 4), (6, 6) 
8 8 171.0  (3, 3), (9, 9) 
9 9 52.3, 52.2 3.74 (s, 3H) (8, 8) 
10 10    
11 11 80.3  (12, 12) 
12 12 28.4, 28.3 
1.51, 1.44 (s(2), 
9H) 
(11, 11), (12, 12) 


















































Figure B-5. ESI+-MS of N-Boc-4-vinyl-4,5-dehydro-L-proline methyl ester 3.3. The 


















































































































































































































Figure B-6. Annotated A) 1H NMR spectrum, B) 13C NMR spectrum, C) COSY, D) HSQC 
and E) HMBC of N-Boc-4-vinyl-4,5-dehydro-L-proline 3.4 and N-Boc-4-vinyl-3,4-
dehydro-L-proline 3.4’ in MeOD. 
 
Table B-3. 13C and 1H NMR of N-Boc-4-vinyl-4,5-dehydro-L-proline 3.4 and N-Boc-4-
vinyl-3,4-dehydro-L-proline 3.4’ (MeOD). 
 
Position 13C shift (ppm) 1H shift (ppm) HMBC Connectivity 
3.4 3.4’ 
2 2 71.4 
4.86, 4.83 (s(2), 
1H) 
3, 5 
3 5 53.0 
4.44-4.19 (m, 
2H) 
3, (4, 4), 5, (6, 6), (8, 8) 
4 4 139.4  3, 5, (6, 6), (7, 7) 
5 3 127.1, 127.0 
5.83-5.75 (m, 
1H) 
(2, 2), 3, 5, (6, 6) 
6 6 131.9 
6.55-6.44 (m, 
1H) 
(3, 3) , (4, 4), (5, 5), (7, 
7) 
7 7 116.6 
5.23-5.08 (m, 
2H) 
(4, 4), (6, 6) 
8 8 177.3, 177.2  3 
10 10    
11 11 81.1  (12, 12) 
12 12 28.9, 28.7 
1.49, 1.46 (s(2), 
9H) 
(11, 11), (12, 12) 
















































Figure B-7. ESI+-MS of N-Boc-4-vinyl-4,5-dehydro-L-proline 3.4. The adduct [M+Na]+ 
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Figure B-8. Annotated A) 1H NMR spectrum, B) 13C NMR spectrum, C) COSY, D) 
NOESY, E) HSQC and F) HMBC of 4-vinyl-4,5-dehydro-L-proline 1.2 in MeOD. 


























































Table B-4. 13C and 1H NMR of 4-vinyl-4,5-dehydro-L-proline 1.2. 
 
Position 13C shift (ppm) 1H shift (ppm) HMBC Connectivity 
2 68.4 5.12 (s, 1H) 5 
3 52.1 4.29 (dd, J=15, 2H) 4, 5, 6 
4 139.3  3, 5, 6, 7 
5 123.1 5.97 (s, 1H) 2, 3, 4, 6 
6 130.1 6.59 (dd, J=18, 11, 1H) 3, 4, 5, 7 
7α 120.3 5.39 (d, J=11, 1H) 4, 6 
7β 120.3 5.31 (d, J=18, 1H) 4, 6 
8    
 
 
Figure B-9. ESI+-MS of 4-vinyl-4,5-dehydro-L-proline 1.2. The adduct [M+Na]+ and 
































PDTDFYSAGGHSLLAVRLRQAVEDEFGMELPLSALLATPTVAGMAARVDAVRAGHDEVDGPDLWADT                            
           * 
 
Figure C-2. Protein coverage (84.1%) map for SibDAT digested with trypsin. The observed 
digested peptides are highlight in yellow while the phosphopantetheinylated peptide is 








Figure C-3. Commonly observed peptide backbone cleavage sites in tandem MS 
experiments and notation of the peptide fragment ions that form as a result. 
 
A) 
Phosphopantetheinylated peptide of interest: VAALWAGLLPGGGIGPDTDFYSAGGHSLLAVR 
                     *  
retention time 32 min 
intensity: 5433 counts 
assigned intensity: 34.1 % 
m/z: 1160.2446 
charge state: 3 
theoretical mass: 3477.6296 Da 
experimental mass: 3477.7102 Da 
mass error: 23.2 ppm 















b2 VA 171.1133 171.1151 -0.0018 135 
b3 VAA                   242.1505 242.1498 0.0007 177 
b4 VAAL 355.2345 355.2339 0.0006 174 
b5 VAALW 541.3138 541.3072 0.0067 111 
b8 VAALWAGL 782.4565 782.4548 0.0017 585 
b9 VAALWAGLL 895.5405 895.5353 0.0052 962 
b13 VAALWAGLL 1163.6577 1163.6411 0.0166 120 
y23* PGGGIGPDTDFYSAGGHS*LLAVR 2584.1050 2584.1799 -0.0750 1794 
y32* 
VAALWAGLLPGGGIGPDTDFYS*AGGHSL
LAVR (Parent ion) 3478.6375 3478.7012 -0.0637 1714 
 
Figure C-4. Mass spectral analysis of phosphopantetheinylated peptide. A) Mass spectral 

























           * 
 
Figure C-5. Protein coverage (72.1%) map for SibDAT digested with trypsin. The observed 
digested peptides are highlight in yellow while the phosphopantetheinylated peptide free 
of and conjugated to tyrosine is highlighted in black. S* denotes the 






































Peptide of interest: VAALWAGLLPGGGIGPDTDFYSAGGHSLLAVR 
                     * 
retention time 30 min 
intensity: 26045 counts 
assigned intensity: 59.3 % 
m/z: 910.9539 
charge state: 4 
theoretical mass: 3639.8298 Da 
experimental mass: 3639.7837 Da 
mass error: -12.7 ppm 















b3 VAA 242.1505 242.1507 -0.0002 190.0 
b4 VAAL 355.2345 355.2368 -0.0023 120.0 
b5 VAALW 541.3138 541.3128 0.0010 190.0 
b6 VAALWA 612.3510 612.3490 0.0020 168.0 
b7 VAALWAG 669.3724 669.3807 -0.0083 117.0 
b8 VAALWAGL 782.4565 782.4554 0.0011 527.0 
b9 VAALWAGLL 895.5405 895.5379 0.0026 892.0 
b11 VAALWAGLLPG 109.6147 1049.5889 0.0259 107.0 
b13 VAALWAGLLPGGG 1163.6577 1163.6541 0.0037 139.0 
b14 VAALWAGLLPGGGI 1276.7417 1276.7415 0.0002 113.0 
y17* PDTDFYSAGGHS*LLAVR 2308.0823 2308.0149 0.0674 1336.0 
y23* PGGGIGPDTDFYSAGGHS*LLAVR 2746.3049 2746.2559 0.0491 3955.0 
y24* LPGGGIGPDTDFYSAGGHS*LLAVR 2859.3889 2859.3464 0.0425 687.0 
y32* 
VAALWAGLLPGGGIGPDTDFYSAGGHS*LLAV
R (Parent ion) 3640.8376 3640.7769 0.0608 5740.0 
 
Figure C-6. Mass spectral analysis of phosphopantetheinylated peptide conjugated to 
tyrosine. A) Mass spectral details on the parent peptide ion. B) Mass spectral details on the 


























Peptide of interest: VAALWAGLLPGGGIGPDTDFYSAGGHSLLAVR 
                     * 
retention time 32 min 
intensity: 60894 counts 
assigned intensity: 40.3 % 
m/z: 1160.2460 
charge state: 3 
theoretical mass: 3477.6296 Da 
experimental mass: 3477.7141 Da 
mass error: 24.3 ppm 















b2 VA 171.1133 171.1137 -0.0004 194 
b3 VAA 242.1505 242.1505 -0.0000 394 
b4 VAAL 355.2345 355.2348 -0.0003 225 
b5 VAALW 541.3138 541.3117 0.0021 306 
b6 VAALWA 612.3510 612.3511 -0.0001 469 
b7 VAALWAG 669.3724 669.3695 0.0029 408 
b8 VAALWAGL 782.4565 782.4546 0.0019 1243 
b9 VAALWAGLL 895.5405 895.5372 0.0034 2659 
b11 VAALWAGLLPG 1049.6147 1049.5836 0.0311 355 
b13 VAALWAGLLPGGG 1163.6577 1163.6504 0.0073 438 
b14 VAALWAGLLPGGGI 1276.7417 1276.7308 0.0109 525 
b15 VAALWAGLLPGGGIG 1333.7632 1276.7308 0.0016 236 
y1 R 175.1195 175.1198 -0.0003 156 
y3 AVR 345.2250 345.2259 0.0009 154 
y4 LAVR 458.3091 458.3069 0.0022 133 
y5 LLAVR 571.3931 571.3926 0.0005 139 
y28* WAGLLPGGGIGPDTDFYSAGGHS*LLAVR 3124.4109 3124.4993 -0.0884 151 
a4 VAAL 327.2396 327.2376 0.0020 137 
a5 VAALW 513.3189 513.3156 0.0033 112 
a8 VAALWAGL 754.4615 754.4587 0.0029 118 
a9 VAALWAGLL 867.5456 867.5405 0.0051 120 
y32* 
VAALWAGLLPGGGIGPDTDFYSAGGHS*LLAVR 
(Parent ion) 3478.6375 3478.7224 -0.0850 15288 
 
Figure C-7. Mass spectral analysis of phosphopantetheinylated peptide not conjugated to 
tyrosine. A) Mass spectral details on the parent peptide ion. B) Mass spectral details on the 

















Peptide of interest: VAALWAGLLPGGGIGPDTDFYSAGGHSLLAVR 
                     * 
retention time 32 min 
intensity: 291178 counts 
assigned intensity: 40.7 % 
m/z: 1160.2478 
charge state: 3 
theoretical mass: 3477.6296 Da 
experimental mass: 3477.7195 Da 
mass error: 24.3 ppm 















b2 VA 171.1133 171.1127 0.0006 530 
b3 VAA 242.1505 242.1499 0.0005 1322 
b4 VAAL 355.2345 355.2334 0.0011 909 
b5 VAALW 541.3138 541.3110 0.0029 1638 
b6 VAALWA 612.3510 612.3513 -0.0004 2150 
b7 VAALWAG 669.3724 669.3721 0.0003 1221 
b8 VAALWAGL 782.4565 782.4539 0.0026 5089 
b9 VAALWAGLL 895.5405 895.5386 0.0020 11397 
b11 VAALWAGLLPG 1049.6147 1049.5830 0.0315 1603 
b12 VAALWAGLLPGG 1106.6362 1106.6400 -0.0040 128 
b13 VAALWAGLLPGGG 1163.6577 1163.6540 0.0035 1769 
b14 VAALWAGLLPGGGI 1276.7417 1276.7408 0.0009 2141 
b15 VAALWAGLLPGGGIG 1333.7632 1333.7632 0.0000 1215 
y1 R 175.1195 175.11989 0.0006 593 
y2 AV 274.1879 274.1863 0.0016 268 
y3 AVR 345.2250 345.2241 0.0009 693 
y4 LAVR 458.3091 458.3079 0.0012 310 
y5 LLAVR 571.3931 571.3933 -0.0002 529 
y26* GLLPGGGIGPDTDFYSAGGHS*LLAVR 2867.2944 2867.3801 -0.0857 4215 
y27* AGLLPGGGIGPDTDFYSAGGHS*LLAVR 2938.3315 2938.4187 -0.0872 3107 
y28* WAGLLPGGGIGPDTDFYSAGGHS*LLAVR 3124.4109 3124.5012 -0.0903 1777 
a4 VAAL 327.2396 327.2396 -0.0003 517 
a5 VAALW 513.3189 513.3167 0.0022 403 
a6 VAALWA 584.3560 584.3550 0.0010 466 
a7 VAALWAG 641.3375 641.3783 -0.0008 262 
a8 VAALWAGL 754.4615 754.4586 0.0029 694 
a9 VAALWAGLL 867.5456 867.5458 -0.0002 722 
y32* 
VAALWAGLLPGGGIGPDTDFYSAGGHS*LLAVR 
(Parent ion) 3478.6375 3478.7271 -0.0896 73771 
 
Figure C-8. Mass spectral analysis of phosphopantetheinylated peptide not conjugated to 
threonine. A) Mass spectral details on the parent peptide ion. B) Mass spectral details on 












Peptide of interest: VAALWAGLLPGGGIGPDTDFYSAGGHSLLAVR 
                     * 
retention time 32 min 
intensity: 121946 counts 
assigned intensity: 38.4 % 
m/z: 1160.2476 
charge state: 3 
theoretical mass: 3477.6296 Da 
experimental mass: 3477.7188 Da 
mass error: 25.6 ppm 















b2 VA 171.1133 171.1139 -0.0006 200 
b3 VAA 242.1505 242.1494 0.0011 523 
b4 VAAL 355.2345 355.2339 0.0006 323 
b5 VAALW 541.3138 541.3110 0.0029 664 
b6 VAALWA 612.3510 612.3487 0.0023 871 
b7 VAALWAG 669.3724 669.3707 0.0016 577 
b8 VAALWAGL 782.4565 782.4544 0.0021 2269 
b9 VAALWAGLL 895.5405 895.5391 0.0014 4707 
b13 VAALWAGLLPGGG 1163.6577 1163.655 0.0023 737 
b14 VAALWAGLLPGGGI 1276.7417 1276.729 0.0125 690 
b15 VAALWAGLLPGGGIG 1333.7632 1333.762 0.0009 113 
y1 R 175.1195 175.1192 0.0003 286 
y2 AV 274.1879 274.1887 -0.0008 104 
y3 AVR 345.2250 345.2245 0.0005 243 
y4 LAVR 458.3091 458.3086 0.0005 159 
y5 LLAVR 571.3931 571.3932 -0.0001 182 
y22* LPGGGIGPDTDFYSAGGHS*LLA 2487.0520 2487.124 -0.0720 385 
y26* WAGLLPGGGIGPDTDFYSAGGHS*LLA 2867.2944 2867.373 -0.0789 1618 
a4 VAAL 327.2396 327.2394 0.0002 248 
a5 VAALW 513.3189 513.3183 0.0006 185 
a6 VAALWA 584.3560 584.3541 0.0019 140 
a7 VAALWAG 641.3375 641.3749 0.0026 120 
a8 VAALWAGL 754.4615 754.4566 0.0049 182 
a9 VAALWAGLL 867.5456 867.5392 0.0064 223 
y32* 
VAALWAGLLPGGGIGPDTDFYSAGGHS*LLAVR 
(Parent ion) 3478.6375 3478.7261 -0.0866 30888 
 
Figure C-9. Mass spectral analysis of phosphopantetheinylated peptide not conjugated to 
1.2. A) Mass spectral details on the parent peptide ion. B) Mass spectral details on the 















Peptide of interest: VAALWAGLLPGGGIGPDTDFYSAGGHSLLAVR 
                     * 
retention time 32 min 
intensity: 163214 counts 
assigned intensity: 39.4 % 
m/z: 1160.2471 
charge state: 3 
theoretical mass: 3477.6296 Da 
experimental mass: 3477.7173 Da 
mass error: 25.2 ppm 















b2 VA 171.1133 171.1122 0.0011 276 
b3 VAA 242.1505 242.1507 -0.0002 702 
b4 VAAL 355.2345 355.2344 0.0001 451 
b5 VAALW 541.3138 541.3106 0.0032 920 
b6 VAALWA 612.3510 612.3497 0.0013 1092 
b7 VAALWAG 669.3724 669.3719 0.0005 696 
b8 VAALWAGL 782.4565 782.4551 0.0014 2929 
b9 VAALWAGLL 895.5405 895.5376 0.0029 6347 
b11 VAALWAGLLPG 1049.6147 1049.588 0.0265 890 
b13 VAALWAGLLPGGG 1163.6577 1163.658 -0.0007 960 
b14 VAALWAGLLPGGGI 1276.7417 1276.738 0.0042 1087 
b15 VAALWAGLLPGGGIG 1333.7632 1333.765 -0.0018 590 
y1 R 175.1195 175.1188 0.0007 343 
y2 AV 274.1879 274.1886 -0.0007 141 
y3 AVR 345.2250 345.2240 0.0010 320 
y4 LAVR 458.3091 458.3046 0.0045 195 
y5 LLAVR 571.3931 571.3920 0.0011 236 
y26* WAGLLPGGGIGPDTDFYSAGGHS*LLA 2867.2944 2867.379 -0.0845 2443 
y27* LWAGLLPGGGIGPDTDFYSAGGHS*LLA 2938.3315 2938.418 -0.0864 1792 
a4 VAAL 327.2396 327.2379 0.0017 288 
a5 VAALW 513.3189 513.3146 0.0043 228 
a6 VAALWA 584.3560 584.3513 0.0047 201 
a7 VAALWAG 641.3375 641.3756 0.0019 155 
a8 VAALWAGL 754.4615 754.4585 0.0031 463 





3478.6375 3478.7250 -0.0874 42775 
 
Figure C-10. Mass spectral analysis of phosphopantetheinylated peptide not conjugated to 
1.5. A) Mass spectral details on the parent peptide ion. B) Mass spectral details on the 





































































































































Figure C-14. Annotated 1H NMR spectrum of L-DOPA-SNAC 4.1a and SNAC in D2O. 
 
Figure C-15. Partially annotated 1H NMR spectrum of L-DOPA-pantetheine 4.1b and 































Figure C-16. ESI+-MS of L-DOPA-SNAC 4.1a. The parent ion [M]+ is detected. 
 
 
Figure C-17. ESI+-MS of L-DOPA-pantetheine 4.1b. The parent ion [M+H]+, adduct 
[M+Na]+, and fragment ions [M-H2O+H]+ , M-C6H11O3+H]+, and [M-C14H20N3O2S+H]+ 
are detected. Formation of the [M-H2O+H]+ fragment ion involves a methyl shift indicated 
by an arrow. Formation of the other two fragment ions involves cleavage at sites indicated 
by dashed lines. 






































































Figure C-18. Nucleotide sequence used to express the condensation domain (SibDC) in 





































































Figure D-2. SDS-PAGE gel images of MLPs A) WP_014988415 and B) WP_011207082 





























Figure D-4. Nucleotide sequences of the genes coding for MLPs A) WP_014988415 and 
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